TABLE OF CONTENTS
| 2 |
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information required by the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with the Securities and Exchange Commission (the “SEC”). You may read and copy any document we file with the SEC at the SEC’s public reference room located at 100 F Street, N.E., Washington, D.C. 20549, U.S.A. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Our SEC filings are also available to the public from the SEC’s internet site athttp://www.sec.gov.
On our Internet website, http://www.earthsciencetech.com, we post the following recent filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.
When we use the terms “ETST”, “Company”, “we”, “our” and “us” we mean Earth Science Tech, Inc., a Nevada corporation, and its consolidated subsidiaries, taken as a whole, as well as any predecessor entities, unless the context otherwise indicates.
FORWARD LOOKING STATEMENTS
This Annual Report containson Form 10-K, the other reports, statements, and information that the Company has previously filed with or furnished to, or that we may subsequently file with or furnish to, the SEC and public announcements that we have previously made or may subsequently make include, may include, or may incorporate by reference certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and that are intended to enjoy the protection of the safe harbor for forward-looking statements.statements provided by that Act. To the extent that any statements made in this report contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements are projectionscan be identified by the use of events, revenues, income, future economic performance or management’s plans and objectives for our future operations. In some cases, you can identify forward-looking statements by terminologywords such as “anticipate”, “estimate”, “plan”, “project”, “continuing”, “ongoing”, “expect”, “believe”, “intend”, “may”, “will”, “should”, “expects”“could”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negativeand other words of these terms or other comparable terminology.similar meaning. These statements are only predictionssubject to risks and involve knownuncertainties that cannot be predicted or quantified and, unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” and the risks set out below, any of which may cause our or our industry’sconsequently, actual results levels of activity, performance or achievements to bemay differ materially different from any future results, levels of activity, performance or achievementsthose expressed or implied by thesesuch forward-looking statements. These risks include, by way of example and not in limitation:
Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any forward-looking statements. These and other factors should be considered carefully and readersAs a result, investors should not place undue reliance on ourthese forward-looking statements. Forward looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
CORPORATE HISTORY
Earth Science Tech, isInc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010 under the name Ultimate Novelty Sports Inc. The Company provided consulting services to the athletic facilities industry and offered a management-consulting firm for fitness facility operators. We focus on assisting independent operatorsfull range of fitness centers,consulting services, including start-up strategy development, membership pricing and management, operational analysis, marketing and public relations and staff training.
On May 6, 2010, the Company formed a wholly owned subsidiary, Ultimate Novelty Sports Inc., an Ontario, Canada Corporation (“UNSI Canada”). On October 30, 2013, pursuant to a sale of subsidiary agreement (the “Sale of Subsidiary Agreement”) the Company sold all of the capital stock of UNSI Canada to Optimal, Inc., a Nevada corporation.
On January 29, 2014, the Company entered into a consulting agreement with Pure Health, Inc. (“Pure”), a Puerto Rican corporation (the “Pure Consulting Agreement”). The purpose of the Pure Consulting Agreement was to retain Pure to consult the Company with regard to the development of health and wellness products as well as start-ups. We consult on a variety of areas,nutritional supplements, including business modelidea generation, preforming and management analysis, staffing issues, customer acquisitiondesigning formulations for products to be used in the health and retention, operational efficiency and marketing strategy, among others. Our objective for each project isnutrition market.
On March 6, 2014, the Company changed its name from Ultimate Novelty Sports, Inc. to develop readily executable plans for our clients. We’ve done work both in North America and Russia, where the fitness industry is highly fragmented and extremely competitive.
On May 28, 2014 the Financial Industry Regulatory Authority (“FINRA”) approved the Name Change and unbiased reviewa change of trading symbol from UNOV to ETST.
On June 6, 2014, the Company filed with the Secretary of State of the overall operationsState of our client’s fitness facility. This analysis can be done with a visitNevada Articles of Amendment to the facility by oneArticles of our consultants or throughIncorporation and a seriesCertificate of phone interviews, emailsDesignation creating a Preferred A class of stock with 10,000,000 preferred A shares (the “Preferred A Shares”) having a par value of $0.001 per share.
On March 6, 2015, the Company entered into a License and business plan analysis. We look at every aspectDistribution Agreement (the “I Vape License and Distribution Agreement”) with I Vape Vapor, Inc. a Minnesota corporation (“I Vape”). Pursuant to the I Vape License and Distribution Agreement the Company licensed to I Vape the rights to use the Company’s Ultra-High Grade CBD Rich Hemp Oil in I Vape’s E-Cigarettes within the U.S. As part of the business fromI Vape License and Distribution Agreement, the services offeredCompany formed Earth Science Tech Vapor One, Inc., a wholly owned Florida corporation subsidiary.
Today, ETST is a biotechnology company focused on unique nutraceuticals and bioceuticals designed to marketingexcel in industries such as health, wellness, nutrition, supplements, cosmetics and overall operations of the fitness facility. At the completion of our analysis, our consultants provide a report to the client that outlines areas that need improvement and a list of recommendationsalternative medicine to improve the quality of life for consumers worldwide. ETST seeks to deliver non-prescription nutritional and dietary supplements that help with treating symptoms such as: chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea, aging and overall wellness. This may include products such as CBD as a natural constituent of hemp oil, vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. These products will be in various formulations and delivery forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.
In particular, ETST is focused on researching and developing innovative hemp extracts and making them accessible worldwide. ETST plans to be a supplier of high quality hemp oil enriched with high-grade CBD. ETST’s primary goal is to advance different high quality hemp extracts with a broad profile of cannabinoids and additional natural molecules found in industrial hemp and to identify their distinct properties.
On January 11, 2019, the Company entered into an agreement with Aaron Decker, and Derrick West, individuals, pursuant to which the Company will transfer, set over and assign to Mr. Decker and Mr. West 95% of the facility.issued and outstanding shares of common stock of Kannabidioid, Inc. This analysis cantransfer of KBD and its business places Mr. Decker and Mr. West or their corporate nominee in full control of KBD for all purposes, subject to their undertaking aggressively and assiduously to pursue the growth of Kannabidioid, Inc.’s business and to maximize its customer base, product line, and profitability. ETST entered into this agreement because management determined that the opportunities for the growth of its other product lines will require that it deploy its resources on these other product lines such that it’s better to allow another management team to build the KBD business. In allowing another management team to build the KBD business, it is expected that ETST will not only continue to benefit from the sales, but it may also be very usefulin a position to clients who runbenefit from its growth without the business daynecessity of deploying additional resources to dayrealize that growth.
On January 11, 2019, the Company received notice that Strongbow Advisors, Inc. (“Strongbow”), and may miss areas that need improvementRobert Stevens (“Stevens”, and together with Strongbow, the “Receiver”) had been appointed by the Nevada District Court, as Receiver for the Registrant in order to increase revenue. Case No. A-18-784952-C.
The end goalCompany sought the appointment of the analysisReceiver after it found itself in an imminent danger of insolvency following the issuance by an arbitration panel of an award (the “Award”) in the sum of $3,994,522.5 million in favor of Cromogen Biotechnology Corporation (“Cromogen”) in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc. (the “Cromogen Litigation”).
The Award consisted of a sum for breach of contract against the Company in the amount of $120,265.00, a sum for costs and fees against the Company in the amount of $111,057.00 and a sum for the claim of tortuous interference and conversion against the Company in the amount of $3,763,200.00. The District Court in Florida had confirmed the Award granted by the arbitration panel, denying however, the award of fees that the arbitration panel had granted Cromogen.
The Cromogen Litigation is now on appeal and the Company is optimistic about its prospects on appeal. Nevertheless, the outcome remains speculative and so notwithstanding its prospects for success on appeal, and faced with such a large judgment and the imminent danger of insolvency, the Company determined that it was in the best interest of its shareholders and creditors to seek protection under receivership and the appointment of a receiver. As of the date of this prospectus, the Company remains in imminent danger of insolvency as the outcome of the Cromogen Litigation remains speculative.
As part of the impact of the receivership, the Court issued a Writ of Injunction or “Blanket Stay” covering the Company and its assets during the time that the Company is in receivership. As a result of the “Blanket Stay” the Company’s estate is protected from creditors and interference with its administration is prevented while the Company’s financial issues are being fully analyzed and resolved. As part of this process, creditors will be notified and required to provide claims in writing under oath on or before the deadline stated in the notice provided by the Receiver or those claims will be barred under NRS §78.675. The Blanket Stay will remain in place unless otherwise waived by the Receiver, or it is vacated by the Court or alternatively, lifted by the Court, upon a “motion to lift stay” duly made and approved by the Nevada District Court.
The appointment of the Receiver was approved unanimously by the Board and by a majority of the Company’s shareholders. Strongbow and Stevens were selected because of their reputation in helping (i) companies restructure and (ii) to execute on their business plans, albeit under a debt and capital structure that allows them to succeed. Stevens and Strongbow assist companies by helping them raise the capital needed not only to pay debts, but build and grow their businesses. The Receiver, however, is an executable planagent of actionthe court, and will be independent and neutral in managing the Company’s operations and trying to preserve the Company’s value for the owners of the gym.
There are a number of large international companies that have workedpossible outcomes to the receivership, including settlement and payment to creditors, reorganization, or liquidation. The intent of the Receiver is to reorganize the Company, pay or settle the Company’s debts and emerge from receivership. If the Receiver is not successful in mitigating the Company’s liabilities, the Company’s results could be materially adversely impacted and the Company may be forced to liquidate its business.
On February 28, 2019, the Company entered into an Equity Financing Agreement (the “GHS Equity Financing Agreement”) and Registration Rights Agreement (the “GHS Registration Rights Agreement”) with Russian fitness facilitiesGHS Investments LLC, a Nevada limited liability company (“GHS”). Under the terms of the Equity Financing Agreement, GHS agreed to provide themthe Company with consultationup to $5,000,000 upon effectiveness of a registration statement on everything from designForm S-1 (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “Commission”).
Following effectiveness of the Registration Statement, the Company shall have the discretion to marketingdeliver puts to GHS and sales.
BUSINESS OVERVIEW
The Company offers high-grade full spectrum cannabinoid oil on the market. There are local companiespositive results in larger citiesstudies on breast cancer and immune cells through the University of Central Oklahoma, in Russia that also provide fitness facility consulting. Among others, one such company is Fitness Service. They provide consulting services that include business plan preparation, marketing strategy development, sales consulting and gym design.
ETST currently has two wholly-owned subsidiaries and favored entity focused on developing its role as a numberworld leader in the CBD space, expanding its work in the pharmaceutical and medical device sectors.
Earth Science Pharmaceutical (“ESP”) is a wholly-owned subsidiary of independent consultants who offer similar servicesETST committed to ours. Among individuals who have worked in fitness facilities previouslythe development of low cost, non-invasive diagnostic tools, medical devices, testing processes and now provide consulting services, a number of Olympic medalists have become fitness facility consultants upon their retirement from professional sports. Due to lower fees than larger corporations, independent consultants are more popular among smaller gymsvaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chains.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of ETST poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development activitiesto explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
Earth Science Foundation (“ESF”) is a favored entity of ETST, effectively being a non-profit organization on February 11, 2019 and is structured to accept grants and donations to conduct further studies and help donate ETST’s effective CBD products to those in need.
Current Operations
CORPORATE STRATEGY
In particular, ETST is focused on researching and developing innovative hemp extracts and making them accessible worldwide. ETST plans to be a supplier of high quality hemp oil enriched with high-grade CBD. ETST’s primary goal is to advance different high quality hemp extracts with a broad profile of cannabinoids and additional natural molecules found in industrial hemp and to identify their distinct properties.
Our missions are to educate the public on the many and varied nutritional and health benefits of CBD-rich hemp oil, to optimize purity in formulation, and to find new product delivery systems. Our corporate strategy in developing our operations is as follows.
To design and produce CBD enhanced nutraceutical products for sale to the general public. We intend to create high-grade CBD-rich hemp oil and other CBD containing products unique to the current market in the future.
To offer a wide selection of health and nutrition products through online, clinics, pharmacies, and in-store retail. Through our wholly owned subsidiary, we plan to continue expanding retail sales of nutritional supplements through online, clinics, pharmacies, and in-store sales. Our product selection includes many high-quality supplement brands, and includes our proprietary CBD-rich hemp oil.
CONSUMER PRODUCTS
We seek to take advantage of an emerging worldwide trend to re-energize the production of hemp and to foster its many uses for consumers. Historically cultivated for industrial and practical purposes, hemp is used today for textiles, paper, auto parts, biofuel, cosmetics, animal feed, nutritional supplements, and much more. The market for hemp-based products is expected to increase substantially over the next five years.
Hemp-based CBD is one full-time employeeof at the present time, consisting of Harvey Katz,least 80 cannabinoids found in hemp, and is non-psychoactive. Our U.S. based operations oversee our Chief Executive Officer, Chief Financial Officer, Secretaryraw material supply chain, raw material processing, product development and Treasurer. Our officersmanufacturing, and directors are responsible for planning, developingsales and operational duties, andmarketing. We will continue to do so throughoutscale-up our processing capability to accommodate new products in our pipeline.
We expect to realize revenue to fund our working capital needs through the early stagessale of finished products and raw materials to third parties. However, in order to fund our drug development efforts, we will need to raise additional capital either through the issuance of equity and/or the issuance of debt. In the event we are unable to raise sufficient additional capital to fund our drug development efforts, we may need to curtail or delay such activity.
Consumer product extraction and quality
We believe our high-grade CBD-rich hemp oil contains the high quality natural CBD because it’s formulated using a wide array of cutting-edge technologies, including super critical extraction process (CO 2), isolation, and micron filtration. Super critical extraction is a gentle approach and the key method in the extraction of our growth.
Our CBD-rich hemp oil does not contain any synthetic cannabinoids and is not an annual reportisolate. It contains everything that is naturally occurring in the original industrial hemp plant. With our high quality CBD-rich hemp oil you benefit from the natural interaction of phytonutrients in their balanced wide-ranging form that may offer the most benefit for overall wellness. Our commercialized CBD based product line, High Grade Full Spectrum Cannabinoids, offers 7 distinct cannabinoids maximizing all the therapeutic benefits the industrial hemp plant has to offer.
Other competitors and companies may use certain methods for extracting hemp including toxic solvents and/or high heat which we believe are unsustainable, dangerous and don’t extract the full balance of nutrients from the industrial hemp plant. One of the most popular processes used to extract hemp oils is alcohol extraction, due to its simplicity and low costs. This may lead to a product that still contains trace amounts of alcohol, as it can be difficult to separate out after extraction. The alcohol extraction used by other companies and our competitors requires the hemp and alcohol mixture to be boiled for long periods of time, potentially damaging sensitive nutrients and important components of the oil. Most companies that claim to be full spectrum only contain 2-5 cannabinoids compared to the 7 we offer in our commercialized batches.
Our CBD-rich hemp oil is sourced from the high quality industrial hemp plants grown by generational family farmers. In order to produce consistent and nutritious CBD-rich oils, these hemp plants are grown domestically currently in Oregon and Kentucky.
We lab test our hemp oil multiple times during the manufacturing process, from seed to shelf. This includes audited financial information to our shareholders. We will make our financial information equally available to any interested parties or investors through compliance with the disclosure rulesbeing tested for a small business issuer under the Securities Exchange Act of 1934. cannabinoid panel content, terpenoids, pesticides, residual solvents, mycotoxins, and micros.
SUBSIDIARIES
The Company’s’ subsidiaries include Earth Science Tech Inc., Nutrition Empire LLC., Cannabis Therapeutics, Inc., Earth Science Pharmaceutical Inc., and Earth Science Foundation, Inc. (all intercompany balances and transactions have been eliminated on consolidation.)
PRODUCT REGULATION
We are subject to disclosure filing requirementslocal and federal laws in our operating jurisdictions. We hold required licenses for product production and distribution and monitor changes in laws, regulations, treaties and agreements.
The Agriculture Improvement Act of 2018 known as the “2018 Farm Bill” is United States federal legislation signed into law on December 20, 2018 which provides much of the legal framework for the hemp-based CBD product category. The 2018 Farm Bill permanently removed “hemp” from the purview of the Controlled Substances Act, and accordingly, the Drug Enforcement Administration (the “DEA”) no longer has any claim to interfere with the interstate commerce of hemp products. Some of the immediate impact from this legislation includes the ability for farmers to access crop insurance and U.S. Department of Agriculture programs for certification and competitive grants. While the DEA is now officially not involved in hemp regulation, the FDA retains its authority to regulate ingestible and topical products, including filing Form 10K annuallythose that contain hemp and Form 10Q quarterly. In addition, we will file Form 8Khemp extracts such as CBD.
A range of federal regulations govern our product development, manufacturing, distribution, sales and marketing, including the Dietary Supplement Health and Education Act of 1994 (the “DSHEA”). Under DSHEA, supplements are effectively regulated by the FDA for Good Manufacturing Practices under 21 CFR Part 111. DSHEA defines a “dietary supplement” as a product intended to supplement the diet that contains one or more of the following: (a) a vitamin; (b) a mineral; (c) an herb or other botanical; (d) an amino acid; (e) a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or (f) a concentrate, metabolite, constituent, extract, or combination of any ingredient described in clause (a) through (e). Thus, the law permits a wide range of dietary ingredients in dietary supplements, including CBD which is an extract of a botanical (Cannabis sativa L.plant). CBD also falls under clause (e) as it is a dietary substance for use by man to supplement the diet by increasing the total dietary intake.
MARKETS
The user market for CBD products and other proxynutraceuticals is generally an individual who has a specific health issue where a health advisor or distributor has provided or directed that user to our product. The market for nutraceuticals is subject to many influential factors, but the main issues affecting the market are consumer spending and information statements from timegovernment regulation.
COMPETITION
The nutraceutical industry is subject to timesignificant competition and pricing pressures. We may experience significant competitive pricing pressures as required.well as competitive products. Several significant competitors may offer products with prices that may match or are lower than ours. We do not intend to voluntarily filebelieve that the above reports in the eventproducts we offer are generally competitive with those offered by other supplement and nutraceutical companies; however, we believe that our obligationproducts are unique and will set themselves apart from competing products. It is possible that one or more of our competitors could develop a significant research advantage over us that allows them to file such reports is suspended under the Exchange Act. provide superior products or pricing, which could put us at a competitive disadvantage. Continued pricing pressure or improvements in research and shifts in customer preferences away from natural supplements could adversely impact our customer base or pricing structure and have a material and adverse effect on our business, financial condition, results of operations and cash flows.
INTELLECTUAL PROPERTY
The public may readCompany has secured, and copy any materials that we filebeen assigned, a provisional patent named “Cannabidiol Compositions and Uses 2” Serial No. 62102538, with the SecuritiesUnited States Patent and Exchange Commission, ("SEC"),Trademark Office (USPTO) for Hemp Oil Enriched with CBD (Cannabidiol) and Hemp Oil Enriched with Proprietary Additives. This patent was filed on January 12, 2014 by the inventors: Dr. Harvey Katz, the former CEO of the Company, Dr. Wei R. Chen, the assistant dean of the College of Mathematics and Science at the SEC's Public Reference RoomUniversity of Central Oklahoma (UCO), and Dr. Feifan Zhou. On January 14, 2014 the inventors Dr. Harvey Katz, Dr. Wei Chen and Dr. Feifan Zhou assigned the Provisional Patent “Cannabidiol Compositions and Uses 2,” Serial No. 62102538, to ETST. A Partial Abstract of new Patent Serial No. 62102538 follows: A composition having cannabidiol, alone, or as a component of hemp oil, for use in treating or preventing cancer. The composition may include D-limonene, which contributes synergistically to the anticancer efficacy of the composition.
With this being the second provisional patent, ETST has a total of ten new claims. Under the sponsorship of ETST, researchers at 100 F Street NE, Washington, DC 20549.the University of Central Oklahoma have been investigating the effects of CBD on immune cells with ETST using the ETST CBD-rich hemp oil. This new patent has been filed because of ETST’s new findings under its sponsorship with the University of Central Oklahoma. We believe that these finding are innovations in this field and may be attributed to ETST’s relationship with its international raw supplier of high quality CBD-rich hemp oil.
Notwithstanding these patent applications, ETST has decided to not pursue patent protection for these products and instead rely on proprietary formulae and trade secrets to protect its intellectual property related to these products. As a result, the Company took an impairment charge of $34,334, writing off the value of these patent applications.
RESEARCH AND DEVELOPMENT
Research and development costs are expensed as incurred. The public may obtain informationCompany’s research and development expenses relate to its engineering activities, which consist of the design and development of new products for specific customers, as well as the design and engineering of new or redesigned products for the industry in general.
Currently the Company is developing its HygeeTM through Earth Science Pharmaceutical, Inc. and further developments on the operationIP formulas through Cannabis Therapeutics, Inc.
EMPLOYEES
As of March 31, 2019, the Public Reference RoomCompany has seven (7) employees. None of our employees are represented by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxya union or covered by a collective bargaining agreement. We have not experienced any work stoppages and information statements, and other information regarding issuers that file electronicallywe consider our relationship with the SEC.
This investment has a high degree of risk. Before you invest you should carefully consider the risks and uncertainties described below and the other information in this prospectus. If any of the following risks actually occur, our business, operating results and financial condition could be harmed and the value of our stock could go down. This means you could lose all or a part of your investment. You should carefully consider the risks described below together with all of the other information included in our public filings before making an investment decision with regard to our securities. The statements contained in or incorporated into this document that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following events described in these risk factors actually occur, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. Moreover, additional risks not presently known to us or that we currently deem less significant also may impact our business, financial condition or results of operations, perhaps materially. For additional information regarding risk factors, see “Forward-Looking Statements.”
Because we have a limited history of operations, and our other ventures are in the development stage or not of yet capitalized, we anticipate our operating expenses will increase prior to earning revenue, and we may never achieve profitability:
The Company launched its first product hemp products in 2015. As we continue to conduct research and development of other CBD and cannabinoid products, we anticipate increases in our operating expenses, without realizing significant revenues from operations. Within the next 12 months, these increases in expenses will be attributed to the cost of (i) administration and start-up costs, (ii) research and development, (iii) advertising, (iv) legal and accounting fees at various stages of operation, (v) joint venture activities, (vi) creating and maintaining distribution and supply chain channels.
As a result of some or all of these factors in combination, the Company may incur losses in the foreseeable future. There is no history upon which to base any assumption as to the likelihood that the Company will prove successful in its research and development projects. We cannot provide investors with any assurance that our business will attract customers and investors. If we were unable to address these risks our business could fail.
Failure to raise additional capital to fund operations could harm our business and results of operations:
Our auditorsprimary source of operating funds from 2015 through the March 31, 2019 fiscal year end has been from revenue generated from proceeds from sales of our CBD products and full spectrum oils powders and gelcaps as well as the sale of our common stock. The Company has experienced net losses from operations since inception, but expects these conditions to improve in 2019 and beyond as it develops its business model. The Company has stockholders’ deficiencies at March 31, 2019 and will require additional financing to fund future operations. Currently, we do not have any firm committed arrangements for financing and can provide no assurance to investors that we will be able to obtain financing when required. No assurance can be given that the Company will obtain access to capital markets in the future or that financing, adequate to satisfy the cash requirements of implementing our business strategies, will be available on acceptable terms. The inability of the Company to gain access to capital markets or obtain acceptable financing could have an adverse effect upon the results of its operations and upon its financial conditions.
We may not have the liquidity to support our future operations and capital requirements.
Whether we can achieve cash flow levels sufficient to support our operations cannot be accurately predicted. Unless such cash flow levels are achieved, we may need to borrow additional funds or sell debt or equity securities, or some combination thereof, to provide funding for our operations. Such additional funding may not be available on commercially reasonable terms, or at all. If adequate funds are not available when needed, our financial condition and operating results would be materially and adversely affected and we may not be able to operate our business without significant changes in our operations, or at all.
We are currently under the control of a court - appointed receiver.
On January 11, 2019, the Company received notice that Strongbow Advisors, Inc., and Robert Stevens had been appointed by the Nevada District Court, as Receiver for the Registrant in Case No. A-18-784952-C.
The company sought the appointment of the Receiver after it found itself in an imminent danger of insolvency following the issuance by an arbitration panel of an award in the sum of $3,994,522.5 million in favor of Cromogen Biotechnology Corporation in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc.
The Award consisted a sum for breach of contract against the Company in the amount of $120,265, a sum for costs and fees against the Company in the amount of $111,057 and a sum for the claim of tortuous interference and conversion against the Company in the amount of $3,763,200. The District Court in Florida had confirmed the Award granted by the arbitration panel, denying however, the award of fees that the arbitration panel had granted Cromogen.
The Cromogen Litigation is now on appeal and the Company is optimistic about its prospects on appeal. Nevertheless, the outcome remains speculative and so notwithstanding its prospects for success on appeal, and faced with such a large judgment and the imminent danger of insolvency, the Company determined that it was in the best interest of its shareholders and creditors to seek protection under receivership and the appointment of a receiver. As of the date of this prospectus, the Company remains in imminent danger of insolvency as the outcome of the Cromogen Litigation remains speculative.
As part of the impact of the receivership, the Court issued a going concern opinion meaning thereWrit of Injunction or “Blanket Stay” covering the Company and its assets during the time that the Company is substantial uncertainty whether we will continue operations.
The appointment of the opinion,Receiver was approved unanimously by the Board and by a majority of the Company’s shareholders. Strongbow and Stevens were selected because of their reputation in helping (i) companies restructure and (ii) to execute on their business plans, albeit under a debt and capital structure that allows them to succeed. Stevens and Strongbow assist companies by helping them raise the capital needed not only to pay debts, but build and grow their businesses. The Receiver, however, is an agent of the court, and will be independent and neutral in managing the Company’s operations and trying to preserve the Company’s value for the creditors and shareholders.
There are a number of possible outcomes to the receivership, including settlement and payment to creditors, reorganization, or liquidation. The intent of the Receiver is to reorganize the Company, pay or settle the Company’s debts and emerge from receivership. If the Receiver is not successful in mitigating the Company’s liabilities, the Company’s results could be materially adversely impacted and the Company may be forced to liquidate its business.
We sell our products in highly competitive markets, which results in pressure on our profit margins and limits our ability to maintain or increase the market share of our services.
The nutraceutical industry is subject to significant competition and pricing pressures. We will experience significant competitive pricing pressures as well as competitive products. Several significant competitors offer products with prices that may match or are lower than ours. We believe that the products we offer are generally competitive with those offered by other supplement and nutraceutical companies. It is possible that one or more of our competitors could develop a significant research advantage over us that allows them to provide superior products or pricing, which could put us at a competitive disadvantage. Continued pricing pressure or improvements in research and shifts in customer preferences away from natural supplements could adversely impact our customer base or pricing structure and have a material and adverse effect on our business, financial condition, results of operations and cash flows.
Marijuana, and Cannabinoids and CBD with more than 0.3% THC are illegal under federal law
Marijuana, and CBD containing in excess of 0.3% THC are Schedule 1 controlled substances and are illegal under federal law, specifically the Controlled Substances Act (21 U.S.C. § 811). Even in states that have legalized the use of marijuana, its sale and use remain violations of federal law. CBD and cannabinoids derived from industrial hemp are not distinguishable. Although the products we buy are certified as THC free, if there was substantial doubt thatwere mistakes in processing or mislabeling and THC were found in our products we could continue as an ongoingbe subject to enforcement and prosecution which would have a negative impact on our business forand operation.
Laws and regulations affecting our industry are constantly changing:
The constant evolution of laws and regulations affecting the next twelve months. We have generated $7,450.00marijuana industry could detrimentally affect our operations. Local, state and federal medical marijuana laws and regulations are broad in revenue forscope and subject to changing interpretations. These changes may require us to incur substantial costs associated with legal and compliance fees and ultimately require us to alter our business plan. Furthermore, violations of these laws, or alleged violations, could disrupt our business and result in a material adverse effect on our operations. In addition, we cannot predict the year ended March 31, 2014. Further, we posted a net lossnature of $39,823.00 forany future laws, regulations, interpretations or applications, and it is possible that regulations may be enacted in the year ended March 31, 2014. These factors, among others, raise substantial doubt about the Company’s abilityfuture that will be directly applicable to continue as a going concern.
Our future successgrowth is largely dependent upon our ability to successfully compete with new and existing competitors by developing or acquiring new products that achieve profitablemarket acceptance with acceptable margins.
Our business operates in markets that are characterized by rapidly changing products, evolving industry standards and potential new entrants. For example, a number of new companies with innovative products, which promise significant health benefits are established every year and are competitive with our products. If these companies gain market acceptance, our ability to grow our business could be materially and adversely affected. Accordingly, our future success depends upon a number of factors, including our ability to accomplish the following: identify emerging trends in our target end-markets; develop, acquire and maintain competitive products; enhance our products by adding innovative features that differentiate us from our competitors; and develop or acquire and bring products to market quickly and cost-effectively. Our ability to develop or acquire new products based on quality research can affect our competitive position and requires the investment of significant resources. These acquisitions and development efforts divert resources from other potential investments in our businesses, and they may not lead to the development of new research or products on a timely basis. New or enhanced products may not satisfy consumer preferences and potential product failures may cause consumers to reject these products. As a result, these products may not achieve market acceptance and our brand image could suffer. In addition, our competitors may introduce superior designs or business strategies, impairing our brand and the desirability of our products, which may cause consumers to defer or forego purchases of our products or services. Also, the markets for our products and services may not develop or grow as we anticipate. The failure of our products to gain market acceptance, the potential for product defects or the obsolescence of our products could significantly reduce our revenue, increase our operating costs or otherwise adversely affect our business, financial condition, results of operations generateor cash from operating activitiesflows.
Our business is dependent on laws pertaining to the cannabis industry:
The federal government has issued guidance to federal prosecutors concerning marijuana enforcement under the Controlled Substances Act (CSA). The Cole Memorandum updates that guidance in light of state ballot initiatives that legalize under state law the possession of small amounts of marijuana and provide for the regulation of marijuana production, processing, and sale. The guidance set forth herein applies to all federal enforcement activity, including civil enforcement and criminal investigations and prosecutions, concerning marijuana in all states.
Congress has determined that marijuana is a dangerous drug and that the illegal distribution and sale of marijuana is a serious crime that provides a significant source of revenue to large-scale criminal enterprises, gangs, and cartels. The Department of Justice is committed to enforcement of the Controlled Substance Act (CSA) consistent with those determinations. The Department is also committed to using its limited investigative and prosecutorial resources to address the most significant threats in the most effective, consistent, and rational way. In furtherance of those objectives, as several states enacted laws relating to the use of marijuana for medical purposes, the Department in recent years has focused its efforts on certain enforcement priorities that are particularly important to the federal government:
| ● | Preventing the distribution of marijuana to minors; |
| ● | Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels; |
| ● | Preventing the diversion of marijuana from states where it is legal under state law in some form to other states; |
| ● | Preventing state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity; |
| ● | Providing the necessary resources and demonstrate the willingness to enforce their laws, and, |
| ● | Enacting regulations in a manner that ensures they do not undermine federal enforcement priorities. |
In jurisdictions that have enacted laws legalizing marijuana in some form, and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale, and possession of marijuana, conduct in compliance with those laws and regulations is less likely to threaten the federal priorities set forth above. Indeed, a robust system may affirmatively address those priorities by, for example, implementing effective measures to prevent diversion of marijuana outside of the regulated system and to other states, prohibiting access to marijuana by minors, and replacing an illicit marijuana trade that funds criminal enterprises with a tightly regulated market in which revenues are tracked and accounted for. In those circumstances, consistent with the traditional allocation of federal-state efforts in this area, enforcement of state law by state and local law enforcement and regulatory bodies should remain the primary means of addressing marijuana-related activity. If state enforcement efforts are not sufficiently robust to protect against the harms set forth above, the federal government may seek to challenge the regulatory structure itself in addition to continuing to bring individual enforcement actions, including criminal prosecutions, focused on those harms.
As with the Department’s previous statements on this subject, this memorandum is intended solely as a guide to the exercise of investigative and prosecutorial discretion. This memorandum does not alter in any way the Department’s authority to enforce federal law, including federal laws relating to marijuana, regardless of state law. Neither the guidance herein nor any state or local law provides a legal defense to a violation of federal law, including any civil or criminal violation of the CSA. Even in jurisdictions with strong and effective regulatory systems, evidence that particular conduct threatens federal priorities will subject that person or entity to federal enforcement action, based on the circumstances. This memorandum is not intended to, does not, and may not be relied upon to create any rights, substantive or procedural, enforceable at law by any party in any matter civil or criminal. It applies prospectively to the exercise of prosecutorial discretion in future cases and does not provide defendants or subjects of enforcement action with a basis for reconsideration of any pending civil action or criminal prosecution. Finally, nothing herein precludes investigation or prosecution, even in the absence of any one of the factors listed above, in particular circumstances where investigation and prosecution otherwise serves an important federal interest.
As to the Company engaging in business outside of the jurisdiction of the U.S.A., the Company must first assume that the laws in other country(s), territories or destinations are similar to that of the U.S. Federal Government, however, the Company must then retain competent legal counsel in this outside jurisdiction and insisting that they understand and obtain a copy of these foreign laws and rules and should gain the expertise and representation of a foreign specialist or attorney in the foreign destination being considered prior to engaging in any cannabis, marijuana or hemp business.
Our business is subject to risk of government action:
While we will use our best efforts to comply with all laws, including federal, state and local laws and regulations, there is a possibility that governmental action to enforce any alleged violations may result in legal fees and damage awards that would adversely affect us.
Because our business is dependent upon continued market acceptance by consumers, any negative trends will adversely affect our business operations:
We are substantially dependent on continued market acceptance and proliferation of consumers of cannabis, medical marijuana and recreational marijuana as well as CBD and full spectrum cannabinoids. We believe that as marijuana becomes more accepted the stigma associated with marijuana use will diminish and as a result consumer demand will continue to grow. While we believe that the market and opportunity in the marijuana space continues to grow, we cannot predict the future growth rate and size of the market. Any negative outlook on the marijuana industry will adversely affect our business operations.
In addition, it is believed by many that large well-funded businesses may have a strong economic opposition to the cannabis industry. We believe that the pharmaceutical industry clearly does not want to cede control of any product that could generate significant revenue. For example, medical marijuana will likely adversely encroach, impact or displace the existing market for the current marijuana pill Marinol, sold by the mainstream pharmaceutical industry. The pharmaceutical industry is well funded with a strong and experienced lobby that eclipses the funding of the medical marijuana movement. Any inroads the pharmaceutical industry could make in halting the impending cannabis industry could have a detrimental impact on our business.
The possible FDA Regulation of cannabis marijuana and CBD, and the possible registration of facilities where cannabis is grown and CBD products are produced, if implemented, could negatively affect the cannabis industry generally, which could directly affect our financial condition:
The FDA has not approved cannabis, marijuana, industrial hemp or CBD derived from cannabis or industrial hemp as a safe and effective drug for any indication. The FDA considers these substances illegal Schedule 1 drugs. As of the date of this filing, we have not, and do not intend to file an IND with the FDA, concerning any of our products that may contain cannabis, industrial hemp or CBD derived from industrial hemp. Further, The FDA has concluded that products containing cannabis, marijuana industrial hemp or CBD derived from industrial hemp are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the U.S. Food, Drug & Cosmetic Act, respectively. Our products are not marketed or sold as dietary supplements. However, at some indeterminate future time, the FDA may choose to change its position concerning products containing cannabis, marijuana, or CBD derived from industrial hemp, and may choose to enact regulations that are applicable to such products, including, but not limited to: the growth, cultivation, harvesting and processing of cannabis and marijuana; regulations covering the physical facilities where cannabis and marijuana are grown; and possible testing to determine efficacy and safety of CBD. In this hypothetical event, our industrial hemp based products containing CBD may be subject to regulation. In the hypothetical event that some or all of these regulations are imposed, we do not know what the impact would be on the cannabis industry in general, and what costs, requirements and possible prohibitions may be enforced. If we are unable to comply with the conditions and possible costs of possible regulations and/or registration as may be prescribed by the FDA, we may be unable to continue to operate our business.
We may have difficulty accessing the service of banks:
On February 14, 2014, the U.S. government issued rules allowing banks to legally provide financial services to state-licensed marijuana businesses. A memorandum issued by the Justice Department to federal prosecutors re-iterated guidance previously given, this time to the financial industry that banks can do business with legal marijuana businesses and “may not” be prosecuted. The Treasury Department’s Financial Crimes Enforcement Network (FinCEN) issued guidelines to banks that it is possible to provide financial services to state-licensed marijuana businesses and still be in compliance with federal anti-money laundering laws. The guidance falls short of the explicit legal authorization that banking industry officials had pushed the government to provide and to date, it is not clear if any banks have relied on the guidance and taken on legal marijuana companies as clients. The aforementioned policy may be administration dependent and a change in presidential administrations may cause a policy reversal and retraction of current policies, wherein legal marijuana businesses may not have access to the banking industry.
Banking regulations in our business are costly and time consuming:
In assessing the risk of providing services to a marijuana-related business, a financial institutions may conduct customer due diligence that includes: (i) verifying with the appropriate state authorities whether the business is duly licensed and registered; (ii) reviewing the license application (and related documentation) submitted by the business for obtaining a state license to operate its marijuana-related business; (iii) requesting from state licensing and enforcement authorities available information about the business and related parties; (iv) developing an understanding of the normal and expected activity for the business, including the types of products to be sold and the type of customers to be served (e.g., medical versus recreational customers); (v) ongoing monitoring of publicly available sources for adverse information about the business and related parties; (vi) ongoing monitoring for suspicious activity, including for any of the red flags described in this guidance; and (vii) refreshing information obtained as part of customer due diligence on a periodic basis and commensurate with the risk. With respect to information regarding state licensure obtained in connection with such customer due diligence, a financial institution may reasonably rely on the accuracy of information provided by state licensing authorities, where states make such information available. These regulatory reviews may be time consuming and costly. Currently we are not licensed and have operated in a manner to avoid the necessity of licensure by not using products containing THC, nevertheless CBD and cannibinoids are still part of the cannabis plant and as such are considered schedule 1 drugs, as such many banks will not transact business with us. We have been successful to date in finding merchant credit card processing and a bank that will do business with us. If either of them decided to cease doing business with us we would not have a way to receive payment and our operations would be negatively affected unless we could find a new bank or processor that would work with us, of which there can be no assurance.
Due to our involvement in the cannabis industry, we may have a difficult time obtaining the various insurances that are desired to operate our business, which may expose us to additional financing.risk and financial liability:
Insurance that is otherwise readily available, such as general liability, and directors and officer’s insurance, is more difficult for us to find, and more expensive, because we are service providers to companies in the cannabis industry. There are no guarantees that we will be able to find such insurances in the future, or that the cost will be affordable to us. If we are forced to go without such insurances, it may prevent us from entering into certain business sectors, may inhibit our growth, and may expose us to additional risk and financial liabilities.
The Company’s industry is highly competitive and we have less capital and resources than many of our competitors which may give them an advantage in developing and marketing products similar to ours or make our products obsolete:
We are involved in a highly competitive industry where we may compete with numerous other companies who offer alternative methods or approaches, who may have far greater resources, more experience, and personnel perhaps more qualified than we do. Such resources may give our competitors an advantage in developing and marketing products similar to ours or products that make our products obsolete. There can be no assurance that we will be able to generate sufficient cash from operations, sell additional sharessuccessfully compete against these other entities.
Our products and services are new and our industry is rapidly evolving:
Due consideration must be given to our prospects in light of common stockthe risks, uncertainties and difficulties frequently encountered by companies in their early stage of development, particularly companies in the rapidly evolving legal cannabis industry. To be successful in this industry, we must, among other things:
| ● | develop and introduce functional and attractive service offerings; |
| ● | attract and maintain a large base of consumers; |
| ● | increase awareness of our brands and develop consumer loyalty; |
| ● | establish and maintain strategic relationships with distribution partners and service providers; |
| ● | respond to competitive and technological developments; |
| ● | attract, retain and motivate qualified personnel. |
We cannot guarantee that we will succeed in achieving these goals, and our failure to do so would have a material adverse effect on our business, prospects, financial condition and operating results.
Some of our products and services are new and are only in early stages of commercialization. We are not certain that these products and services will function as anticipated or borrow additional funds. Our inabilitybe desirable to obtain additional cashits intended market. Also, some of our products may have limited functionalities, which may limit their appeal to consumers and put us at a competitive disadvantage. If our current or future products and services fail to function properly or if we do not achieve or sustain market acceptance, we could lose customers or could be subject to claims which could have a material adverse effect on our business, financial condition and operating results.
As is typical in a new and rapidly evolving industry, demand and market acceptance for recently introduced products and services are subject to a high level of uncertainty and risk. Because the market for the Company is new and evolving, it is difficult to predict with any certainty the size of this market and its growth rate, if any. We cannot guarantee that a market for the Company will develop or that demand for Company’s products and services will emerge or be sustainable. If the market fails to develop, develops more slowly than expected or becomes saturated with competitors, our business, financial condition and operating results would be materially adversely affected.
Adverse publicity or consumer perception of our products and any similar products distributed by others could harm our reputation and adversely affect our sales and revenues.
We believe we are highly dependent upon positive consumer perceptions of the safety and quality of our products as well as similar products distributed by other health and wellness companies. Consumer perception of health products, nutrition supplements and our products in particular can be substantially influenced by scientific research or findings, national media attention and other publicity about product use. Adverse publicity from these sources regarding the safety, quality or efficacy of nutritional supplements and our products could harm our reputation and results of operations. The mere publication of news articles or reports asserting that such products may be harmful or questioning their efficacy could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such news articles or reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.
Our operating results may fluctuate, which makes our results difficult to predict and could cause our results to fall short of expectations.
Our operating results may fluctuate as a result of a number of factors, many of which may be outside of our control. As a result, comparing our operating results on a period-to-period basis may not be meaningful, and you should not rely on our past results as an indication of our future performance. Our quarterly, year-to-date, and annual expenses as a percentage of our revenues may differ significantly from our historical or projected rates. Our operating results in future quarters may fall below expectations. Each of the following factors may affect our operating results:
| ● | our ability to deliver products in a timely manner in sufficient volumes; | |
| ● | our ability to recognize product trends; | |
| ● | our loss of one or more significant customers; | |
| ● | the introduction of successful new products by our competitors; | |
| ● | adverse media reports on the use or efficacy of nutritional supplements; and | |
| ● | our inability to make our online division profitable. |
Because our business is changing and evolving, our historical operating results may not be useful to you in predicting our future operating results.
The loss of key management personnel could adversely affect our business.
We depend on the continued services of our executive officers and senior management team as they work closely with independent representative and are responsible for our day-to-day operations. Our success depends in part on our ability to retain our executive officers, to compensate our executive officers at attractive levels, and to continue to attract additional qualified individuals to our management team. Although we have entered into employment agreements with members of our senior management team, and do not believe that any of them are planning to leave or retire in the near term, we cannot assure that our senior managers will remain with us. The loss or limitation of the services of any of our executive officers or members of our senior management team, or the inability to attract additional qualified management personnel, could have a material adverse effect on our business, financial condition, results of operations, or independent associate relations.
Independent Sales Representatives could fail to comply with our policies and procedures or make improper product, compensation, marketing or advertising claims that violate laws or regulations, which could result in claims against us that could harm our financial condition and operating results.
We sell our products through a sales force of independent representatives. The independent representatives are independent contractors and, accordingly, we are not in a position to provide the same direction, motivation, and oversight as we would if associates were our own employees. As a result, there can be no assurance that our representatives will participate in our marketing strategies or plans, accept our introduction of new products, or comply with our policies and procedures. All independent representatives will be required to sign a written contract and agree to adhere to our policies and procedures, which prohibit associates from making false, misleading or other improper claims regarding products or income potential from the distribution of the products. However, independent representatives may from time to time, without our knowledge and in violation of our policies, create promotional materials or otherwise provide information that does not accurately describe our marketing program. There is a possibility that some jurisdictions could seek to hold us responsible for independent representatives activities that violate applicable laws or regulations, which could result in government or third-party actions or fines against us, which could harm our financial condition and operating results.
Uncertainty of profitability:
Our business strategy may result in increased volatility of revenues and earnings. As we only have a limited number of products developed at this time, our overall success will depend on a limited number of products and our ability to develop or find new ones or new applications as well as our research and development efforts, which may cause variability and unsteady profits and losses depending on the products offered and their market acceptance.
Our revenues and our profitability may be adversely affected by economic conditions and changes in the market for medical and recreational marijuana. Our business is also subject to general economic risks that could adversely impact the results of operations and its abilityfinancial condition.
Because of the anticipated nature of the products that we offer and attempt to continuedevelop, it is difficult to accurately forecast revenues and operating results and these items could fluctuate in existence. The financial statements do notthe future due to a number of factors. These factors may include, any adjustments that might result fromamong other things, the outcomefollowing:
| ● | Our ability to raise sufficient capital to take advantage of opportunities and generate sufficient revenues to cover expenses. | |
| ● | Our ability to source strong opportunities with sufficient risk adjusted returns. | |
| ● | Our ability to manage our capital and liquidity requirements based on changing market conditions generally and changes in the developing legal medical marijuana and recreational marijuana industries. | |
| ● | The acceptance of the terms and conditions of our service. | |
| ● | The amount and timing of operating and other costs and expenses. | |
| ● | The nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment return expectations. | |
| ● | Adverse changes in the national and regional economies in which we will participate, including, but not limited to, changes in our performance, capital availability, and market demand. | |
| ● | Adverse changes in the projects in which we plan to invest which result from factors beyond our control, including, but not limited to, a change in circumstances, capacity and economic impacts. | |
| ● | Adverse developments in the efforts to legalize marijuana or increased federal enforcement. | |
| ● | Changes in laws, regulations, accounting, taxation, and other requirements affecting our operations and business. | |
| ● | Our operating results may fluctuate from year to year due to the factors listed above and others not listed. At times, these fluctuations may be significant. |
Management of this uncertainty.
Successful expansion of our business will be seriously harmed.
We are entering a potentially highly competitive and has relatively low barriers to entry. Our competitors vary in size andmarket:
The markets for businesses in the varietymedical marijuana and recreational marijuana industries as well as their related CBD and cannabinoid industries are competitive and evolving. In particular, we face strong competition from larger companies that may be in the process of offering similar products and services they offer.to ours. Many of our current and potential competitors have longer operating histories, significantly greater financial, technical, marketing and other resources and an establishedlarger client base. These competitorsbases than we have (or may be ableexpected to devote greater resources tohave).
Given the promotionrapid changes affecting the global, national, and sales of their services than we can. If we fail to compete successfully against our competitors our business could be harmed.
Although we believe that our CBD and Full Spectrum products are exempt from regulation under the CSA, the U.S. Patent and Trademark Office may disagree and disallow us from obtaining trademark and patent protection for our brand and products.
We have applied for a patent for one of our products. Because it contains CBD, and may be considered an illegal Schedule 1 drug under federal law, the U.S. Patent and Trademark Office may not approve our pending applications for patent or trademark protection for our products, and this could materially affect our ability to establish and grow our brand, products and develop our customer base and good will.
If we fail to protect our intellectual property, our business could be adversely affected:
Our viability will depend, in part, on our ability to develop and maintain the proprietary aspects of our products and brands to distinguish our products from our competitors’ products. We rely on patents, copyrights, trademarks, trade secrets, and confidentiality provisions to establish and protect our intellectual property. Any infringement or misappropriation of our intellectual property could damage its value and limit our ability to compete. We may have to engage in litigation to protect the rights to our intellectual property, which could result currentin significant litigation costs and potential shareholdersrequire a significant amount of our time. Competitors may also harm our sales by designing products that mirror the capabilities of our products or technology without infringing on our intellectual property rights. If we do not obtain sufficient protection for our intellectual property, or if we are unable to effectively enforce our intellectual property rights, our competitiveness could lose confidence in our financial reporting,be impaired, which would harmlimit our businessgrowth and future revenue. We may also find it necessary to bring infringement or other actions against third parties to seek to protect our intellectual property rights. Litigation of this nature, even if successful, is often expensive and time-consuming to prosecute, and there can be no assurance that we will have the trading pricefinancial or other resources to enforce our rights or be able to enforce our rights, or prevent other parties from developing similar technology or designing around our intellectual property.
Our lack of sufficient patent and/or trademark or copyright protection and any unauthorized use of our stock.
We currently rely on a combination of Directors is relatively inexperienced with U.S. GAAPprotections by patents and the related internal control procedures required of U.S. public companies. Althoughcontracts, including confidentiality and nondisclosure agreements, and common law rights, such as trade secrets, to protect our Chief Financial Officer is experienced in accounting requirements and procedures generally accepted in the Russian Federation, management has determined that she requires additional training and assistance in U.S. GAAP matters. Management has determined that our internal audit function is also significantly deficient due to insufficient qualified resources to perform internal audit functions. Finally, we have not established an Audit Committee of our Board of Directors.
Ordinary and necessary business deduction other than the cost of goods sold are disallowed by the CommitteeInternal Revenue Services for Cannabis companies under IRC Section 280E:
At this juncture, we do not believe that IRS 280E interferes with our businesses model from deducting ordinary and necessary business expenses because we believe that we are in compliance with the 2014 Farm Bill and/or the products we sell are either from participants that are compliant with the 2014 Farm Bill or are made from lawfully imported industrial hemp full spectrum cannabinoids or CBD. Although we believe that the Farm Bill applies to commercial activity in that it references the “marketing,” “sale” and “transportation,” of Sponsoring Organizationsindustrial hemp and hemp products that are derived from an authorized state program, it is possible that our suppliers may not be in compliance with the Farm Bill or that a government agency or prosecutor could take a narrower view of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework. A material weakness is a deficiency,activity allowed under the Farm Bill or a combination of deficiencies, in internal control over financial reporting, suchimport laws, if that there is a reasonable possibility that a material misstatement ofwere the company's annual or interim financial statements will not be prevented or detected on a timely basis. For these reasons, we are considering the costs and benefits associated with improving and documenting our disclosure controls and procedures and internal controls and procedures, which includes (i) hiring additional personnel with sufficient U.S. GAAP experience and (ii) implementing ongoing training in U.S. GAAP requirements for our CFO and accounting and other finance personnel. If the results of these efforts are not successful, or if material weaknesses are identified in our internal control over financial reporting, our management will be unable to report favorably as to the effectiveness of our internal control over financial reporting and/or our disclosure controls and procedures, andcase we could be requiredseen as selling and distributing a Schedule 1 substance under the CSA and we would therefore be subject to further implement expensiveIRC Section 280E. IRC Section 280E only allows the cost of goods sold to be deducted from revenues earned from the sale of cannabis and time-consuming remedial measurescannabis products that come under the purview of the CSA. If that were the case we would not be able to deduct many of our overhead expenses. To the extent that we have subsidiaries and potentially lose investor confidenceother lines of trade or business, many of those overhead expenses could be allocated to those subsidiaries that are note involved in products that come within the CSA so we would have an opportunity to deduct those disallowed expenses elsewhere. Nevertheless, the revenue that is derived from those other trade or businesses may not be as large as the corresponding deductions so be may still not be able to realize the full benefit of those expenses and instead have net operating losses in the accuracyother trade or businesses that we would not be able to use or would have to carry-forward indefinitely. In addition, if the Company enters the cannabis industry more directly, for example if the company were to purchase a marijuana dispensary that was legal under state law and completenessoperated in compliance with state law, IRC Section 280E would unquestionably be applicable in which case the onerous tax burden might significantly impact the profitability of the Company and may make the pricing of its products less competitive, to the extent that competitors could manage to find a way to not have their operations subject to IRC Section 280E. Notwithstanding the forgoing, there can be no assurance that if we were to reallocate items of deduction form business segments that were involved in the sales of products coming within the CSA that the Internal Revenue Service (“IRS”) would not challenge those deductions or disallow them on some other basis. This could result in an onerous tax burden.
We may be held responsible for certain taxes or assessments relating to the activities of our financial reportsindependent representatives, which could harm our financial condition and operating results.
Our independent representatives are subject to taxation and, in some instances, legislation or governmental agencies impose an obligation on us to collect taxes, such as value added taxes, and to maintain appropriate tax records. In addition, we are subject to the risk in some jurisdictions of being responsible for social security and similar taxes with respect to our distributors. In the event that local laws and regulations require us to treat our independent contractors as employees, or if our reps are deemed by local regulatory authorities to be our employees, rather than independent contractors, we may be held responsible for social security and related taxes in those jurisdictions, plus any related assessments and penalties, which could harm our financial condition and operating results.
Risks Related to Our Securities
Because we may issue additional shares of our common stock, investment in our company could be subject to substantial dilution:
Investors’ interests in our Company will be diluted and investors may suffer dilution in their net book value per share when we issue additional shares. We are authorized to issue 75,000,000 shares of common stock, $0.001 par value per share. As of March 31, 2019 there were 52,205,400 shares issued and outstanding and as of June 25, 2019 there were 52,160,400 shares of our common stock issued and outstanding. We anticipate that all or at least some of our future funding, if any, will be in the form of equity financing from the sale of our common stock. If we do sell more common stock, investors’ investment in our company will likely be diluted. Dilution is the difference between what investors pay for their stock and the net tangible book value per share immediately after the additional shares are sold by us. If dilution occurs, any investment in our company’s common stock could seriously decline in value.
Trading in our common stock on the OTCQB Exchange has been subject to wide fluctuations:
Our common stock is currently quoted for public trading on the OTCQB Exchange. The trading price of our common stock has been subject to wide fluctuations. Trading prices of our common stock may fluctuate in response to a number of factors, many of which will be beyond our control. The stock market has generally experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies with limited business operation. There can be no assurance that trading prices and price earnings ratios previously experienced by our common stock will be matched or maintained. These broad market and industry factors may adversely affect the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted. Such litigation, if instituted, could result in substantial costs for us and a diversion of management’s attention and resources.
Our common stock is currently quoted only on the OTCQB marketplace, which may have an adverse effectunfavorable impact on our stock price and potentially subjectliquidity:
Our common stock is quoted on the OTCQB Marketplace. The OTCQB Marketplace is a significantly more limited market than the New York Stock Exchange or the NASDAQ stock market. The quotation of our shares of common stock on the OTCQB Marketplace may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the trading price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.
There can be no assurance that there will be an active market for our shares of common stock either now or in the future. Market liquidity will depend on the perception of our operating business and any steps that our management might take to bring us to litigation. the awareness of investors. There can be no assurance given that there will be any awareness generated. Consequently, investors may not be able to liquidate their investment or liquidate at a price that reflects the value of the business. As a result, holders of our securities may not find purchasers for our securities should they desire to sell them. Consequently, our securities should be purchased only by investors having no need for liquidity in their investment and who can hold our securities for an indefinite period of time.
The regulation of penny stocks by SEC and FINRA may discourage the tradability of our securities.
We are a “penny stock” company. None of our securities currently trade in any market and, if ever available for trading, will be subject to a Securities and Exchange Commission rule that imposes special sales practice requirements upon broker-dealers who sell such securities to persons other than established customers or Accredited Investors. For purposes of the rule, the phrase “Accredited Investors” means, in general terms, institutions with assets in excess of $5,000,000, or individuals having a net worth in excess of $1,000,000 or having an annual income that exceeds $200,000 (or that, when combined with a spouse’s income, exceeds $300,000). For transactions covered by the rule, the broker-dealer must make a special suitability determination for the purchaser and receive the purchaser’s written agreement to the transaction prior to the sale. Effectively, this discourages broker-dealers from executing trades in penny stocks. Consequently, the rule will affect the ability of purchasers of our stock to sell their securities in any market that might develop therefore because it imposes additional regulatory burdens on penny stock transactions.
In addition, the Securities and Exchange Commission has adopted a number of rules to regulate “penny stocks”. Such rules include Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5, 15g-6, 15g-7, and 15g-9 under the Securities and Exchange Act of 1934, as amended. Because our securities constitute “penny stocks” within the meaning of the rules, the rules would apply to us and to our securities. The rules will further affect the ability of owners of shares to sell our securities in any market that might develop for them because it imposes additional regulatory burdens on penny stock transactions.
Shareholders should be aware that, according to Securities and Exchange Commission, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii) “boiler room” practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities.
Nevada law, our Articles of Incorporation and our by-laws provides for the indemnification of our officers and directors at our expense, and correspondingly limits their liability, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for the benefit of officers and/or directors:
Our Articles of Incorporation and By-Laws include provisions that eliminate the personal liability of our directors for monetary damages to the fullest extent possible under the laws of the State of Nevada or other applicable law. These provisions eliminate the liability of our directors and our shareholders for monetary damages arising out of any violation of a director of his fiduciary duty of due care. Under Nevada law, however, such provisions do not eliminate the personal liability of a director for (i) breach of the director’s duty of loyalty, (ii) acts or omissions not in good faith or involving intentional misconduct or knowing violation of law, (iii) payment of dividends or repurchases of stock other than from lawfully available funds, or (iv) any transaction from which the director derived an improper benefit. These provisions do not affect a director’s liabilities under the federal securities laws or the recovery of damages by third parties.
We do not intend to pay cash dividends on any investment in the foreseeable future. Any return on investment may be limited to the valueshares of stock of our common stock.
We have never paid any cash dividends and currently do not intend to pay any cash dividends for the foreseeable future. To the extent that we require additional funding currently not provided for, in our financing plan, our funding sources may likely prohibit the payment of a dividend. Because we do not currently intend to declare dividends, any gain on an investment in Earth Science Tech Inc.our company will need to come through appreciationan increase in the stock’s price. This may never happen and investors may lose all of their investment in our company.
Because our securities are subject to penny stock rules, you may have difficulty reselling your shares:
Our shares as penny stocks, are covered by Section 15(g) of the stock’s price.
Our common stock market prices may be volatile, which substantially increases the risk that investors may not be able to sell their shares.
Because of the limited trading market for our common stock will ever develop. Asand because of the possible price volatility, shareholders may not be able to sell their shares of common stock when desired. The inability to sell Securities in a rapidly declining market may substantially increase the risk of loss because of such illiquidity and because the price for our Securities may suffer greater declines because of our price volatility.
Certain factors, some of which are beyond our control, that may cause our share price to fluctuate significantly include, but are not limited to the following:
● variations in our quarterly operating results;
● loss of a key relationship or failure to complete significant transactions;
● additions or departures of key personnel; and
● fluctuations in stock market price and volume.
Additionally, in recent years the stock market in general, and the personal care markets in particular, have experienced extreme price and volume fluctuations. In some cases, these fluctuations are unrelated or disproportionate to the operating performance of the underlying company. These market and industry factors may materially and adversely affect our stock price, regardless of our operating performance. In the past, class action litigation often has been brought against companies following periods of volatility in the market price of those companies common stock. If we become involved in this type of litigation in the future, it could result stockholdersin substantial costs and diversion of management attention and resources, which could have a further negative effect on shareholders’ investments in our stock.
Because we may be unable to liquidate their investments, or may encounter considerable delay in sellingissue additional shares of our common stock.
Investors’ interests in our Company will be diluted and investors may not developsuffer dilution in their net book value per share when we issue additional shares. We are authorized to issue 75,000,000 shares of common stock, $0.001 par value per share. As of the date hereof there are 52,160,400 shares of our common stock issued and outstanding. We anticipate that all or at least some of our future funding, if any, will be in the future,form of equity financing from the sale of our common stock. If we do sell more common stock, investors’ investment in our company will likely be diluted. Dilution is the difference between what investors pay for their stock and if one does develop, itthe net tangible book value per share immediately after the additional shares are sold by us. If dilution occurs, any investment in our company’s common stock could seriously decline in value.
FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock:
In addition to the “penny stock” rules described above, the Financial Industry Regulatory Authority (known as “FINRA”) has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be sustained. Ifsuitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common shares, which may limit your ability to buy and sell our stock and have an active tradingadverse effect on the market does develop,for our shares.
Our existing stockholders may experience significant dilution from the sale of our common stock pursuant to the GHS financing agreement.
The sale of our common stock to GHS Investments LLC in accordance with the Financing Agreement may have a dilutive impact on our shareholders. As a result, the market price of our common stock could decline. In addition, the lower our stock price is likely to be highly volatile due to, among other things,at the naturetime we exercise our put options, the more shares of our business and because we are a new public company with a limited operating history. Further, even if a public market develops, the volume of trading in our common stock we will presumably be limited and likely be dominated byhave to issue to GHS in order to exercise a few individual stockholders. put under the Financing Agreement.
The limited volume, if any, will makeperceived risk of dilution may cause our stockholders to sell their shares, which may cause a decline in the price of our common stock. Moreover, the perceived risk of dilution and the resulting downward pressure on our stock subjectprice could encourage investors to manipulation by one or more stockholders and will significantly limitengage in short sales of our common stock. By increasing the number of shares offered for sale, material amounts of short selling could further contribute to progressive price declines in our common stock.
The issuance of shares pursuant to the GHS financing agreement may have a significant dilutive effect.
Depending on the number of shares we issue pursuant to the GHS Financing Agreement, it could have a significant dilutive effect upon our existing shareholders. Although the number of shares that one canwe may issue pursuant to the Financing Agreement will vary based on our stock price (the higher our stock price, the less shares we have to issue), there may be a potential dilutive effect to our shareholders, based on different potential future stock prices, if the full amount of the Financing Agreement is realized. Dilution is based upon common stock put to GHS and the stock price discounted to GHS’s purchase or sell in a short period of time.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTY AND EQUIPMENT.
On August 14, 2017, the Company executed a lease for a 1,981 square foot office/warehouse space in Miami, FL to be used for corporate offices and storage of our common shares and increase your transaction costs to sell those shares.inventory. The Securities and Exchange Commission has adopted Rule 3A51-1, which establishes the definition of a “Penny Stock,” for the purposes relevant to us, as any equity security that has market price of less than $5.00 per share or within an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15G-9 require:
On January 11, 2019, the Company received notice that Strongbow Advisors, Inc., and Robert Stevens had been appointed by the Nevada District Court, as Receiver for the Registrant in Case No. A-18-784952-C.
The company sought the appointment of the Receiver after it found itself in an imminent danger of insolvency following the issuance by an arbitration panel of an award in the sum of $3,994,522.5 million in favor of Cromogen Biotechnology Corporation in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc.
The Award consisted a sum for breach of contract against the Company in the amount of $120,265, a sum for costs and fees against the Company in the amount of $111,057 and a sum for the claim of tortuous interference and conversion against the Company in the amount of $3,763,200. The District Court in Florida had confirmed the Award granted by the arbitration panel, denying however, the award of fees that the arbitration panel had granted Cromogen.
The Cromogen Litigation is now on appeal and the Company is optimistic about its prospects on appeal. Nevertheless, the outcome remains speculative and so notwithstanding its prospects for success on appeal, and faced with such a large judgment and the imminent danger of insolvency, the Company determined that it was in the best interest of its shareholders and creditors to seek protection under receivership and the appointment of a receiver. As of the date of this prospectus, the Company remains in imminent danger of insolvency as the outcome of the Cromogen Litigation remains speculative.
As part of the impact of the receivership, the Court issued a Writ of Injunction or “Blanket Stay” covering the Company and its assets during the time that the Company is in receivership. As a result of the “Blanket Stay” the Company’s estate is protected from creditors and interference with its administration is prevented while the Company’s financial issues are being fully analyzed and resolved. As part of this process, creditors will be notified and required to provide claims in writing under oath on or before the deadline stated in the notice provided by the Receiver or those claims will be barred under NRS §78.675. The Blanket Stay will remain in place unless otherwise waived by the Receiver, or it is vacated by the Court or alternatively, lifted by the Court, upon a “motion to lift stay” duly made and approved by the Nevada District Court.
The appointment of the Receiver was approved unanimously by the Board and by a majority of the Company’s shareholders. Strongbow and Stevens were selected because of their reputation in helping (i) companies restructure and (ii) to execute on their business plans, albeit under a debt and capital structure that allows them to succeed. Stevens and Strongbow assist companies by helping them raise the capital needed not currentlyonly to pay debts, but build and grow their businesses. The Receiver, however, is an agent of the court, and will be independent and neutral in managing the Company’s operations and trying to preserve the Company’s value for the creditors and shareholders.
There are a partynumber of possible outcomes to any legal proceedings,the receivership, including settlement and we arepayment to creditors, reorganization, or liquidation. The intent of the Receiver is to reorganize the Company, pay or settle the Company’s debts and emerge from receivership. If the Receiver is not aware of any pending or potential legal actions.
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Our common stock is currently quoted on the OTC Bulletin Board.OTCQB under the symbol “ETST”. Our common stock has been quoted on the OTC QBOTCQB since August 29, 2012,27, 2017, under the symbol “ETST”. The Company is DTC eligible effective October 4, 2012.
The following table sets forth the high and low bid quotations for our common stock as reported on the OTCQB for the periods indicated.
| Fiscal 2018 | Low | High | ||||||
| First Quarter – reported June 30, 2017 | $ | 0.61 | $ | 1.75 | ||||
| Second Quarter – reported September 30, 2017 | $ | 0.53 | $ | 0.923 | ||||
| Third Quarter – reported December 31, 2017 | $ | 0.722 | $ | 1.50 | ||||
| Fourth Quarter – reported March 31, 2018 | $ | 0.56 | $ | 1.62 | ||||
| Fiscal 2019 | Low | High | ||||||
| First Quarter – reported June 30, 2018 | $ | 0.421 | $ | 0.96 | ||||
| Second Quarter – reported September 30, 2018 | $ | 0.45 | $ | 1.64 | ||||
| Third Quarter – reported December 31, 2018 | $ | 0.525 | $ | 2.45 | ||||
| Fourth Quarter – reported March 31, 2019 | $ | 0.55 | $ | 0.929 | ||||
| Fiscal 2020 | Low | High | ||||||
| First Quarter – reported June 27, 2019 | $ | 0.301 | $ | 0.9499 | ||||
HOLDERS
As of March 31, 2014,2019, there were 58recordare 157 record holders of 35,980,00051,930,400 shares of the Company'sCompany’s common stock.
DIVIDENDS
We have not paid any cash dividends on our common stock since our inception and do not intend to date and does not anticipate or contemplate payingpay any dividends in the foreseeable future.
The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is theour present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.
UNREGISTERED SALES OF SECURITIES
The following shares sold and issued were shares of management to utilize all available funds forrestricted Common Stock made in reliance upon the developmentexemptions from registration provided by Section 4(2) of the Company's business.
During the twelve months ended March 31, 20142019, the Company issued 5,780,193 shares of its common stock for $2,069,752.00, in transactions that were exempt from registration under the Securities Act of 1933, as amended pursuant to Section 4(2) and/or Rule 506 promulgate under Regulation D. No gain or loss was recognized on the issuances. On April 2, 2018 the Company issued 10,000 shares to an investor at a price of $0.45 per share. On April 4, 2018 the Company 100,000 shares to an investor at a price of $0.30 per share. On April 9, 2018 the Company issued 5,000 shares to an individual for marketing services valued at $0.70 per share. On April 10, 2018 the Company issued 20,000 shares to an investor at a price of $0.30 per share. On April 16, 2018 the Company issued 25,000 and 50,000 shares to two investors at $0.30 per share. On April 17, 2018 the Company issued 100,000 shares to an investor at $0.30 per share. On April 19, 2018 the Company issued 25,000 shares to an investor at a price of $0.30 per share. On April 24, 2018 the Company issued the Company issued 10,000 shares to an investor at a price of $0.40 per share. On April 24, 2018 the Company issued 45,000 shares to an investor at a price of $0.30 per share. On April 26, 2018 the Company issued 15,000 shares to an investor at a price of $0.40 per share. On April 30, 2018 the Company issued 50,000 share to an investor at a price of $0.30 per share. On April 30, 2018 the Company issued 200 and 400 shares to two individuals as compensation for their sales efforts for the Company’s products at a price of $0.72 per share. On May 1, 2018 the Company issued 100,000 shares to an investor at a price of $0.30 per share. On May 1, 2018 the Company issued 25,000 shares for marketing services valued at $0.79 per share. On May 2, 2018 the Company issued 50,000 shares to an investor at $0.30 per share. On May 7, 2018 the Company issued 50,000 and 12,500 shares to two investors at $0.30 and $0.40 per share respectively. On May 10, 2018 the Company issued 100,000 shares to each of two investors at a price of $0.30 per share each. On May 13, 2018 the Company issued 28,500 shares to an investor at $0.35 per share. On May 14, 2018 the Company issued 33,334 shares to each of two investors at a price of $0.30 per share each. On June 15, 2018 the Company issued 15,000 shares to an individual for marketing services valued at $0.64 per share. On June 21, 2018 the Company issued 30,000 shares to an investor at a price of $0.35 per share. On June 26, 2018 the Company issued 20,000 shares, 30,000 shares, 200,000 shares and 200,000 shares to four investors at $0.25 per share, $0.35 per share, $0.20 per share and $0.20 per share respectively. On June 28, 2018 the Company issued 32,000 and 14,500 shares to two investors at $0.25 per share and $0.35 per share respectively. On June 30, 2018 the Company issued 2,500 shares, 50,000 shares, 10,000 shares 5,000 shares, 50,000 shares, 5,000 shares and 5,000 shares to its officers and tor sales and marketing compensation to 9 individuals at $0.80 per share. On July 2, 2018 the Company issued 100,000 shares to an investor at a price of $0.25 per share. On July 3, 2018 the Company 40,000 shares to an investor at a price of $0.20 per share. On July 5, 2018 the Company issued 30,000 shares to an investor at a price of $0.25 per share. On July 5, 2018 the Company issued 100,000 shares to an investor at a price of $0.25 per share. On July 6, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On July 10, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On July 25, 2018 the Company issued 20,000 shares to an investor at a price of $0.25 per share. On July 31, 2018 the Company issued 5,000 shares, 5,000 shares, 5,000 shares, 5,000 shares for marketing compensation to 4 individuals at $0.74 per share. On August 3, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On August 21, 2018 the Company issued 20,000 shares to an investor at $0.30 per share. On August 21, 2018 the Company issued 40,000 shares to an investor at $0.25 per share. On August 22, 2018 the Company issued 200,000 shares to an investor at $0.25 per share. On August 24, 2018 the Company issued 40,000 shares and 32,258 shares to two investor at $0.25 per share. On August 31, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On September 3, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On September 5, 2018 the Company issued 100,000 shares and 100,000 shares to two investors at $0.25 per share. On September 6, 2018 the Company issued 40,000 shares to an investor at $0.25 per share. On September 7, 2018 the Company issued 20,000 shares to an investor at $0.25 per share. On September 12, 2018 the Company issued 40,000 shares to an investor at $0.25 per share. On September 14, 2018 the Company issued 10,000 shares to an investor at $0.25 per share. On September 14, 2018 the Company issued 40,000 shares to an investor at $0.25 per share. On September 17, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On September 18, 2018 the Company issued 50,000 shares to an investor at $0.50 per share. On September 19, 2018 the Company issued 100,000 shares to an investor at $0.25 per share. On September 21, 2018 the Company issued 20,000 shares and 100,000 shares to two investors at $0.50 per share. On September 24, 2018 the Company issued 4,000 shares to an investor at $0.60 per share. On September 24, 2018 the Company issued 10,000 shares to an investor at $0.50 per share. On September 26, 2018 the Company issued 30,000 shares to an investor at $0.50 per share. On September 27, 2018 the Company issued 20,000 shares and 100,000 shares to two investors at $0.50 per share. On September 28, 2018 the Company issued 7,000 shares to an investor at $0.50 per share. On September 28, 2018 the Company issued 20,000 shares to an investor at $0.40 per share. On September 30, 2018 the Company issued 2,500 shares, 50,000 shares, 10,000 shares, 50,000 shares, 10,000 shares to its officers 5 individuals at $1.26 per share. On October 1, 2018 the Company issued 25,000 shares to an investor at a price of $0.50 per share. On October 2, 2018 the Company issued 20,000 shares each to two investors at a price of $0.50 per share in blocks of 10,000 shares. On October 9, 2018 the Company issued 10,000 shares to an existing investor at a price of $0.75 per share. On October 15, 2018 the Company issued 6,000 shares to an investor at a price of $0.95 per share. On October 29, 2018 the Company issued 40,000 shares to an investor at a price of $0.50 per share. On November 5, 2018 the Company issued 100,000 shares to an investor at a price of $0.45 per share. On November 8, 2018 the Company issued 20,000 shares to an investor at a price of $0.50 per share. On November 30, 2018 the Company issued 10,000 shares to an investor at a price of $0.50 per share. On December 3, 2018 the Company issued 15,000 shares to an officer at a price of $0.90 per share. On December 5, 2018 the Company issued 75,000 shares to two investors at a price of $0.40 per share. On December 10, 2018 the Company issued 17,000 shares to an investor at a price of $0.30 per share. On December 11, 2018 the Company issued 16,667 shares, 34,000 shares , and 34,000 shares to 2 investors and an investor couple at a price of $0.30 per share. On December 13, 2018 the Company issued 35,000 shares to an existing investor at a price of $0.30 per share. On December17, 2018 the Company issued 35,000 shares and 100,000 shares to 2 investors at a price of $0.30 per share. On December 18, 2018 the Company issued 100,000 shares, 100,000 shares, 30,000 shares, 100,000 shares, and 20,000 shares to 5 existing investors at a price of $0.30 per share. On December 20, 2018 the Company issued 35,000 shares to an existing investor at a price of $0.30 per share. On December 31, 2018 the Company issued 2,500 shares, 50,000 shares, 10,000 shares, 50,000 shares, 10,000 shares to each of its 5 individual officers at $0.79 per share. On January 2, 2019 the Company issued 5,000 shares to a sales representative at $0.78 per share. On January 9, 2019 the Company issued 35,000 shares to an investor at $0.30 per share. On January 28, 2019 the Company issued 25,000 shares to an investor at $0.40 per share. On February 1, 2019 the Company issued 100,000 shares to an investor at $0.30 per share. On February 27, 2019 the Company issued 100,000 shares to an investor at $0.30 per share. On March 11, 2019 the Company issued 100,000 shares to an investor at $0.30 per share. On March 19, 2019 the Company issued 100,000 shares to an investor at $0.30 per share. On March 25, 2019 the Company issued 50,000 shares and 50,000 shares to two investors at $0.30 per share. On March 31, 2013.
EQUITY COMPENSATION PLAN INFORMATION
The Company currently does not have an offeringequity compensation plan in place.
COMMON STOCK
The holders of 6,700,000our common stock are entitled to one vote per share on all matters submitted to a vote of our stockholders. The holders of the common stock have the sole right to vote, except as otherwise provided by law, by our articles of incorporation, or in a statement by our board of directors in a Preferred Stock Designation.
In addition, such holders are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds, subject to the payment of preferential dividends or other restrictions on dividends contained in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of preferred stock described above. In the event of the dissolution, liquidation or winding up of Earth Science Tech, Inc., the holders of our common stock are entitled to share ratably in all assets remaining after payment of all our liabilities, subject to the preferential distribution rights granted to the holders of any series of our preferred stock in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of our preferred stock described above.
The holders of the common stock do not have cumulative voting rights or preemptive rights to acquire or subscribe for additional, unissued or treasury shares in accordance with the laws of the State of Nevada. Accordingly, excluding any voting rights granted to any series of our preferred stock, the holders of more than 50 percent of the issued and outstanding shares of the common stock voting for the election of directors can elect all of the directors if they choose to do so, and in such event, the holders of the remaining shares of the common stock voting for the election of the directors will be unable to elect any person or persons to the board of directors. All outstanding shares of the common stock are fully paid and nonassessable.
The laws of the State of Nevada provide that the affirmative vote of a majority of the holders of the outstanding shares of our common stock at a priceand any series of $0.001 per shareour preferred stock entitled to vote thereon is required to authorize any amendment to our Directors Larissa Zabelina (3,500,000) and Elena Mochkina (3,200,000)articles of incorporation, any merger or consolidation of Earth Science Tech, Inc. with any corporation, or any liquidation or disposition of any substantial assets of Earth Science Tech, Inc..
PREFERRED STOCK
The Company initially Designated Ten Million (10,000,000) shares of Class A Preferred Stock, $0.001 par value, on June 6, 2014 by filing said designation with the Nevada Secretary of State (the “Preferred Stock”). The total amount received from this Offering was $6,700. We completed this offering pursuantholders of shares of Preferred Stock are entitled to Regulation Svote on all matters coming to a vote of the Securities Act.
WARRANTS
The Company does not currently have any warrants issued or outstanding.
ISSUER REPURCHASES OF EQUITY SECURITIES
We did not repurchase any shares of our common stock listed above were affected in reliance onduring the exemptions for sales of securities not involving a public offering, as set forth in Regulation S promulgated under the Securities Act.
OPTIONS
The Company has not granted any former U.S. citizen subject to Section 877 of the Internal Revenue Code, any corporation, or partnership organized or existing under the laws of the United States of America or any state, jurisdiction, territory or possession thereof and any estate or trust the income of whichoptions since inception.
TRANSFER AGENT
The Company’s transfer agent is subject to U.S. federal income tax irrespective of its source, and within the meaning of U.S. securities laws, as defined in Rule 902(o) of Regulation S, means: (i) any natural person resident in the United States; (ii) any partnership or corporation organized or incorporated under the laws of the United States; (iii) any estate of which any executor or administrator is a U.S. person; (iv) any trust of which any trustee is a U.S. person; (v) any agency or branch of a foreign entity located in the United States; (vi) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (vii) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (viii) any partnership or corporation if organized under the laws of any foreign jurisdiction, and formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.
| 28 |
Not applicable to a smaller“smaller reporting companycompany” as defined by Rule 12b-2in Item 10(f)(1) of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
The following discussion of our financial condition and results of operations for the years ended March 31, 2019 and March 31, 2018 should be read in conjunction with our auditedconsolidated financial statements and the notes theretoto those statements that are included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, orAnnual Report on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-lookingForm 10-K. Our discussion includes forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimatescurrent expectations that involve risks and assumptions that are inherently subject to significant business, economicuncertainties, such as our plans, objectives, expectations and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actualintentions. Actual results and the timing of events could cause actual results to differ materially from those expressedanticipated in any forward lookingthese forward-looking statements made by, or our behalf.as a result of a number of factors. We disclaim any obligationuse words such as “anticipate”, “estimate”, “plan”, “project”, “continuing”, “ongoing”, “expect”, “believe”, “intend”, “may”, “will”, “should”, “could”, and similar expressions to updateidentify forward-looking statements.
OVERVIEW
We offer high-grade full spectrum cannabinoid oil to the market through our website and store front/clinic accounts. Through our positive results in studies on breast cancer and immune cells through the University of Operations
Our medical device division is committed to the developing low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Our CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. We’re currently working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
Our R&D division is poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. We have invested in research and development to explore and harness the medicinal power of CBD. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
Our favored division effectively became a non-profit organization on February 11, 2019 and is structured to accept grants and donations to conduct further studies and help donate EST’s effective CBD products to those in need.
We expect to realize revenue from our consumer products business segment to fund our working capital needs. However, in order to fund our pharmaceutical product development efforts, we will need to raise additional capital either through the issuance of equity and/or the issuance of debt. In the event we are unable to fund our drug development efforts, we may need to curtail or delay such activity.
RESULTS OF OPERATIONS
The following tables set forth summarized cost of revenue information for the year ended March 31, 2019 and for the year ended March 31, 2018:
| For the Years Ended | ||||||||
| March 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenue | $ | 770,635 | $ | 463,108 | ||||
| Cost of revenues | 475,622 | 270,222 | ||||||
| Gross Profit | 295,013 | 192,886 | ||||||
We had product sales of $770,635 and gross profit of $295,013, representing a gross margin of 38.2% in 2019 compared with product sales of $463,108 and gross profit of $192,886, representing a gross margin of 41.6% in 2018. The sales increase in 2019 compared with 2018 is primarily due to an increase in distribution, customer awareness and demand for our brandedHigh Grade Full Spectrum Cannabinoidsproducts, as we continued to expand and maintain our core customer base.
OPERATING EXPENSE
A reconciliation from our net income (loss) to Adjusted EBITDA, a non-GAAP measure, for the years ended March 31, 2019 and 2018 are outlined in the table below:
| Fiscal Year Ended March 31, 2019 and March 31, 2018 | ||||||||||||||||
| 2019 | 2018 | $ Change | % Change | |||||||||||||
| Compensation - officers | $ | 223,404 | $ | 260,936 | $ | (37,532 | ) | -16 | % | |||||||
| Officer Compensation Stock | $ | 424,055 | $ | 170,775 | $ | 253,280 | 59 | % | ||||||||
| Marketing | $ | 242,719 | $ | 332,986 | $ | (90,267 | ) | -37 | % | |||||||
| General and administrative | $ | 514,467 | $ | 653,242 | $ | (138,775 | ) | -26 | % | |||||||
| Donations | $ | - | $ | 35,500 | $ | (35,500 | ) | 0 | ||||||||
| Loss on disposal of assets | $ | - | $ | 60,792 | $ | (60,792 | ) | 0 | ||||||||
| Patent Impairment Expense | $ | 34,334 | $ | - | $ | 34,334 | 100 | % | ||||||||
| Professional fees | $ | 172,127 | $ | 70,289 | $ | 101,838 | 59 | % | ||||||||
| Bad Debt Expense | $ | 31,211 | 87,342 | $ | (56,131 | ) | -179 | % | ||||||||
| Cost of legal proceedings | $ | 453,553 | $ | 79,447 | $ | 374,106 | 82 | % | ||||||||
| Research and development | $ | 338,856 | 150,451 | $ | 188,405 | 55 | % | |||||||||
| Total operating expenses | $ | 2,434,726 | $ | 1,901,760 | $ | 532,966 | 21 | % | ||||||||
| Loss from operations | (2,139,713 | ) | (1,708,874 | ) | $ | 430,839 | 20 | % | ||||||||
| Other Income (Expenses) | ||||||||||||||||
| Interest expense | $ | (75,632 | ) | $ | (4,773 | ) | $ | |||||||||
| Interest income | - | 3 | ||||||||||||||
| Total other income (expenses) | (75,632 | ) | (4,765 | ) | ||||||||||||
| Net loss before income taxes | (2,215,345 | ) | (1,713,639 | ) | ||||||||||||
| Income taxes | - | - | ||||||||||||||
| Net loss | $ | (2,215,345 | ) | $ | (1,713,639 | ) | ||||||||||
| Net loss per common share: | ||||||||||||||||
| Loss per common share-Basic and Diluted | $ | (0.04 | ) | $ | (0.04 | ) | ||||||||||
For the year ended March 31, 20142019 the Company had a net loss from continuing operations of approximately $2,215,345 compared to the year ended March 31, 2013
Year Ended March 31, 2013 | Year Ended March 31, 2013 | Increase (Decrease) % | |||||||
| Advertising | $ | - | $ | 5,200 | |||||
| Professional fees | 36,711 | 24,883 | |||||||
| Consulting | - | 12,500 | |||||||
| Officer compensation | 2,700 | 3,600 | |||||||
| Salaries | - | 36,758 | |||||||
| Other | 6,856 | 11,521 | |||||||
| Travel expense | - | 2,168 | |||||||
| Website development cost | - | - | |||||||
| $ | 46,267 | $ | 96,630 | ||||||
General and promotion of our services to potential customers. As a result, we incurred $19,197 in website development costs, an amount that represents 46.15% of our total operating costs for the year ended March 31, 2012.
INTEREST EXPENSE
Interest expense increased to $75,632 in 2019 compared with $4,765 in 2018.
NON-GAAP FINANCIAL MEASURES
We use Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplement the information provided by our GAAP measures. Adjusted EBITDA is defined by us as EBITDA (net income (loss) plus depreciation expense, amortization expense, interest and income tax expense, minus income tax benefit), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it more clearly highlight trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.
We use Adjusted EBITDA in communicating certain aspects of fitness products.
| Working Capital | Year Ended March 31, 2014 | Year Ended March 31, 2013 | ||||||
| Current Assets | $ | 554,954 | $ | 4,756 | ||||
| Current Liabilities | $ | 205,861 | $ | 67,824 | ||||
| Working Capital | $ | 349,093 | $ | (63,068 | ) | |||
Adjusted EBITDA is not presented in accordance with, or as an alternative to, GAAP financial measures and may be different from non-GAAP measures used by other companies. We encourage investors to review the GAAP financial measures included in this Annual Report, including our consolidated financial statements, to aid in their analysis and understanding of our performance and in making comparisons.
CASH FLOW & ASSETS
A summary of our changes in cash flows & assets for the periods indicated, provides selected cash flow information:
| March 31, 2019 | March 31, 2018 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 127,524 | $ | 72,038 | ||||
| Accounts Receivable(net allowance of $128,420 and $111,301 respectively) | $ | 70,934 | $ | 69,050 | ||||
| Prepaid expenses and other current assets | 33,751 | 6,033 | ||||||
| Inventory | 161,309 | 134,784 | ||||||
| Total current assets | 393,518 | 281,905 | ||||||
| Property and equipment, net | 11,362 | 18,490 | ||||||
| Other Assets: | ||||||||
| Patent, net | — | 38,740 | ||||||
| Deposits | 6,191 | 6,191 | ||||||
| Total other assets | 6,191 | 44,931 | ||||||
| Total Assets | $ | 411,071 | $ | 345,326 | ||||
| LIABILITIES AND STOCKHOLDERS’S EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 98,109 | $ | 80,439 | ||||
| Accrued expenses | $ | 85,440 | $ | 93,987 | ||||
| Accrued settlement | 231,323 | 231,323 | ||||||
| Notes payable - related parties | 59,558 | 59,558 | ||||||
| Total current liabilities | 617,730 | 465,307 | ||||||
| Total liabilities | 617,730 | 465,307 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ (Deficit) Equity: | ||||||||
| Convertible preferred stock with liquidation preference, par value of $0.001 pre share,10,000,000 shares authorized: 5,200,000 issued and outstanding | 5,200 | 5,200 | ||||||
| Common stock, par value $0.001 per share, 75,000,000 shares authorized; 52,205,400 and 46,150,207 shares issued and outstanding as of March 31, 2019 and March 31, 2018 respectively | 52,206 | 46,150 | ||||||
| Additional paid-in capital | 27,449,487 | 25,326,876 | ||||||
| Accumulated deficit | (27,713,552 | ) | (25,498,207 | ) | ||||
| Total stockholders’ (Deficit)Equity | (206,659 | ) | (119,981 | |||||
| Total Liabilities and Stockholders’ (Deficit) Equity | $ | 411,071 | $ | 345,326 | ||||
| 31 |
Year Ended March 31, 2014 | Year Ended March 31, 2013 | |||||||
| Cash provided by (used in) operating activities | $ | (43,721 | ) | $ | (51,023 | ) | ||
| Cash used in investing activities | $ | - | $ | - | ||||
| Cash provided by financing activities | $ | 415,415,669 | $ | 44,125 | ||||
| Net increase (decrease) in cash | $ | 371,948 | $ | (6,898 | ) | |||
For the year ended March 31, 20142019 the Company had a net loss from continuing operations of approximately $1,713,639 compared to a loss from continuing operations of approximately $1,146,354 for the year ended March 31, 2018. This increase in net loss is due to the ongoing legal fees related to the Cromogen litigation, further advancements in Research and development, and new filing expenses achieving fully reporting status.
Marketing expenses totaled $242,719 for the twelve months ended March 31, 2019, a decrease of $90.267 from $332,986 for the twelve months ended March 31, 2018. This decrease primarily related to the Company focusing on the development on the V4 line and advancements with the HygeeTM medical device.
Research and development costs were totaled $338,856 for the twelve months ended March 31, 2019, an increase of $188,405 from $150,451. This increase is due to further developments of the HygeeTM medical device, new product development and marketing that helped achieve successful V4 batch launch in December and CBD chocolates anticipated to launch mid 2019. We expect that R&D will continue to be consistent with the twelve months ended March 31, 2018 and will increase as well for the foreseeable future. Notwithstanding this increase in R&D Dr. Aube has been successful in receiving grants from the Canadian government for further research. Separate disclosure was not material pursuant to ASC 730, Research and Development.
Total Revenues - For the years ended March 31, 2019 and 2018, the Company had total sales of $770,635 and $463,108, respectively. While our revenues increased, this was consistent with a corresponding increase in our cost of goods sold from $475,622 for the year ended March 31, 2019 to $270,222 for the year ended March 31, 2018 ; resulting in a Gross Profit of $295,019 as of March 31, 2019 compared to $192,886 for the previous year ending March 31, 2018.
Costs and Expenses - Costs of sales, include the costs of manufacturing, packaging, warehousing and shipping our products. As we generated $7,450.00 in revenuesdevelop and release addition products, we expect our costs of sales to increase.
General and administrative expenses decreased by approximately $514,467 for the year ended March 31, 2019 compared to the year ended March 31, 2013 when we generated $41,8882018. The increase can be attributed primarily to the company under going the full reporting process, auditing and filing fees, and uplisting to the OTCQB exchange.
Research and development costs were $338,856 for the twelve months ended March 31, 2019, an increase of $188,405 from $150,451. This increase is due to further developments on the HygeeTM medical device, new product development and marketing that helped achieve successful V4 batch launch in revenues. In addition, duringDecember and CBD chocolates anticipated to launch mid 2019.
Patent impairment expenses totaled $34,334 for the twelve months ended March 31, 2019, an increase of $34,334 from $0 for the twelve months ended March 31, 2018. This increase is due to the Company on relinquishing their current applications. Due to the cost associated for obtaining and maintaining patents as well as certain questions as to patents will ultimately be issued, the Company determined a better course of actions for its proprietary formulas to be kept as trade secrets.
The Company had $127,524 in Cash for the period ended March 31, 2019, compared with $72,038 for the same period ended March 31, 2018. This increase is primarily due to the increase in sales from the V4 launch.
The Company had $98,109 in Accounts Payable for the period ended March 31, 2019, compared with $80,439 for the same period ended March 31, 2018. This increase is primarily due to the remaining balance for the V4 inventory along with all the previous accrued legal fees that are in a monthly payment plan till fully paid..
The Company had $59,558 in Notes Payable and Accrued Interest for the period ended March 31, 2019. The Company had the same amount in Notes Payable and Accrued Interest for the period ended March 31, 2018.
The Company had a Stockholder’s Deficit of $206,659 for the period ended March 31, 2019, compared with $119,981 of Stockholder’s Equity for the same period ended March 31, 2018. This increase is primarily due to the Company obtaining more direct investors to pay for the V4 inventory and HygeeTMadvancements.
We are a smaller reporting company, as defined by 17 CFR § 229.10(f)(1). We do not consider the impact of inflation and changing prices as having a material effect on our net sales and revenues and on income from our operations for the previous two years or from continuing operations going forward.
The Company achieved a gross margin percentage of 38.2% for the year ended March 31, 2013,2019, a decrease of 3.3% from the Company’s Registration Statement ongross margin percentage of 41.6% for the Form S-1/A filed with the Securities and Exchange Commission was declared effective.prior year ended March 31, 2018. The Company had sold 3,580,000 common sharesexpects this gross margin percentage to increase marginally as it achieves greater economies of scale from higher volumes of sales and is consequently able to purchase inventory at $0.01 per sharelower prices.
CASH FLOWS FROM OPERATING ACTIVITIES
Operating Activities - For the years ended March 31, 2019 and March 31, 2018, the Company used cash for total proceedsoperating activities of $35,800 pursuant to this Registration Statement.
CASH FLOWS FROM INVESTING ACTIVITIES
During the year ended March 31, 2012, the President of2019 and March 31, 2018, the Company provided a $25,000 loan to the Company. The loan is payable on demand, unsecured, bears interest at 4.5% per annum (compounded yearly) and consists of $25,000 of principal, and $2,081 of accrued interest payable as of March 31, 2013.
CASH FLOWS FROM FINANCING ACTIVITIES
During the year ended March 31, 2014,2019, the Company had sold 753,000received $1,564,194 in cash proceeds from sales of restricted common shares at $0.50 per share for total proceeds of $376,500.00. In addition, duringstock. For the yearYear ended March 31, 2014, we incurred $0 (March 31, 2013: $0) for management consulting services.
FUTURE FINANCING
On February 28, 2019, the Company entered into an Equity Financing Agreement (the “GHS Equity Financing Agreement”) and Registration Rights Agreement (the “GHS Registration Rights Agreement”) with GHS Investments LLC, a Nevada limited liability company (“GHS”). Under the terms of the Equity Financing Agreement, GHS agreed to provide the Company with up to $5,000,000 upon effectiveness of a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “Commission”).
Following effectiveness of the Registration Statement, the Company shall have the discretion to deliver puts to GHS and GHS will be requiredobligated to purchase shares of the Company’s common stock, par value $0.001 per share based on the investment amount specified in each put notice. Additionally, in accordance with the Equity Financing Agreement, the Company shall issue GHS a promissory note in the formprincipal amount of $30,000 to offset transaction costs (the “Note”).
STOCK BASED COMPENSATION
The Company follows ASC 718 in accounting for its stock based compensation to employees. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized at the time granted.
The Company accounts for transactions in which services are received from non-employees in exchange for equity financinginstruments based on the fair value of the equity instrument exchanged in accordance with ASC 505-50.
RECENT ACCOUNTING PRONOUNCEMENTS
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other, which simplifies the accounting for goodwill impairments by eliminating step 2 from the salegoodwill impairment test. Instead, if “the carrying amount of our common stock. However, we cannot provide investors with any assurancea reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to that weexcess, limited to the total amount of goodwill allocated to that reporting unit.” The guidance is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will be able to raise sufficient funding from the sale of our common stockhave on its Consolidated Financial Statements.
All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or through a loan from our directors to meet our obligations over the next twelve months. We do not have any arrangements in place for any future equity financing.
OFF- BALANCE SHEET ARRANGEMENTS
None.
Not applicable to a smaller“smaller reporting companycompany” as defined by Rule 12b-2in Item 10(f)(1) of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
The financial statements required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report.
Notes to Financials
For
Earth Science Tech Corporation
For the Fiscal Year Ending
March 31, 2014
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Boardshareholders and the board of Directors and Stockholders
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheetsheets of Earth Science Tech Inc. (A Development Stage Company) (the “Company”) (F.K.A Ultimate Novelty Sports, Inc.)Corporation as of March 31, 20142019 and 2018, the related statements of operations, stockholders’ equity (deficit), and cash flows for the yearyears then ended, and from inception (April 19, 2007)the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2014. 2019 and 2018, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.
Basis for Opinion
These financial statements are the responsibility of the Company'sCompany’s management. Our responsibility is to express an opinion on thesethe Company’s financial statements based on our audits.
We conducted our auditsaudit in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not requiredmisstatement, whether due to have, nor were we engagederror or fraud.
Our audit included performing procedures to perform, an auditassess the risks of its internal control overmaterial misstatement of the financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing auditstatements, whether due to error or fraud, and performing procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includesrespond to those risks. Such procedures included examining, on a test basis, evidence supportingregarding the amounts and disclosures in the financial statements, assessingstatements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation.statements. We believe that our audits provideaudit provides a reasonable basis for our opinion.
Substantial Doubt about the financial statements referredCompany’s Ability to above present fairly, in all material respects, the financial position of Earth Science Tech, Inc. (A Development Stage Company) (F.K.A Ultimate Novelty Sports, Inc.)Continue as of March 31, 2014 and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations whichand has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about itsthe Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
| /S/ BF Borgers CPA PC | |
| BF Borgers CPA PC | |
| We have served as the Company’s auditor since 2017 | |
| Lakewood, CO | |
| June 28, 2019 |
2580 Anthem Village Drive, Henderson, NV 89052 Phone: (702) 563-1600 Fax: (702) 920-8049
CONSOLIDATED BALANCE SHEETS
| March 31, | March 31, | |||||||
| 2014 | 2013 | |||||||
| Current Assets: | ||||||||
| Cash | $ | 376,704 | $ | 4,756 | ||||
| Deposits | 178,250 | - | ||||||
| Total current assets | 554,954 | 4,756 | ||||||
| Total Assets | $ | 554,954 | $ | 4,756 | ||||
| LIABILITIES AND STOCKHOLDERS'S (EQUITY/DEFICIT) | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 745 | $ | 24,543 | ||||
| Due to related parties | 166,511 | 16,200 | ||||||
| Loan payable - related parties | 38,605 | 27,081 | ||||||
| Total current liabilities | 205,861 | 67,824 | ||||||
| Total liabilities | 205,861 | 67,824 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' (Deficit): | ||||||||
| Common stock, par value $0.001 per share, 75,000,000 | ||||||||
| shares authorized; 35,980,000 and 10,280,000 shares | ||||||||
| issued and outstanding as of March 31, 2014 and March 31, 2013 respectively | 35,980 | 10,280 | ||||||
| Additional paid-in capital | 12,932,004 | 32,220 | ||||||
| Stock payable | 376,500 | - | ||||||
| Services receivable | (12,850,000 | ) | - | |||||
| (Deficit) accumulated during the development stage | (145,391 | ) | (105,568 | ) | ||||
| Total stockholders' (equity/deficit) | 349,093 | (63,068 | ) | |||||
| Total Liabilities and Stockholder's (Equity/Deficit) | $ | 554,954 | $ | 4,756 | ||||
| March 31 2019 | March 31, 2018 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 127,524 | $ | 72,038 | ||||
| Accounts Receivable(net allowance of $128,420 and $ 111,301 respectively) | $ | 70,934 | $ | 69,050 | ||||
| Prepaid expenses and other current assets | 33,751 | 6,033 | ||||||
| Inventory | 161,309 | 134,784 | ||||||
| Total current assets | 393,518 | 281,905 | ||||||
| Property and equipment, net | 11,362 | 18,490 | ||||||
| Other Assets: | ||||||||
| Patent, net | 38,740 | |||||||
| Deposits | 6,191 | 6,191 | ||||||
| Total other assets | 6,191 | 44,931 | ||||||
| Total Assets | $ | 411,071 | $ | 345,326 | ||||
| LIABILITIES AND STOCKHOLDERS’S EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 98,109 | $ | 80,439 | ||||
| Accrued expenses | $ | 85,440 | $ | 93,987 | ||||
| Accrued settlement | 231,323 | 231,323 | ||||||
| Convertible Note 1-GHS | 113,300 | |||||||
| Promissory Note-GHS | 30,000 | |||||||
| Notes payable - related parties | 59,558 | 59,558 | ||||||
| Total current liabilities | 617,730 | 465,307 | ||||||
| Total liabilities | 617,730 | 465,307 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ (Deficit) Equity: | ||||||||
| Convertible preferred stock with liquidation preference, par value of $0.001 pre share,10,000,000 shares authorized: 5,200,000 issued and outstanding | 5,200 | 5,200 | ||||||
| Common stock, par value $0.001 per share, 75,000,000 shares authorized; 52,205,400 and 46,150,207 shares issued and outstanding as of March 31, 2019 and March 31, 2018 respectively | 52,206 | 46,150 | ||||||
| Additional paid-in capital | 27,449,487 | 25,326,876 | ||||||
| Accumulated deficit | (27,713,552 | ) | (25,498,207 | ) | ||||
| Total stockholders’ (Deficit)Equity | (206,659 | ) | (119,981 | ) | ||||
| Total Liabilities and Stockholders’ (Deficit) Equity | $ | 411,071 | $ | 345,326 | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS
| Cumulative | ||||||||||||
| Year | Year | From Inception | ||||||||||
| Ended | Ended | (April 23, 2010) | ||||||||||
| March 31, | March 31, | Through March 31, | ||||||||||
| 2014 | 2013 | 2014 | ||||||||||
| Revenue | $ | 7,450 | $ | 41,888 | $ | 72,769 | ||||||
| Cost of Revenues | 900 | 6,762 | 11,940 | |||||||||
| Gross Profit | 6,550 | 35,126 | 60,829 | |||||||||
| Expenses: | ||||||||||||
| General and administrative: | ||||||||||||
| Advertising | - | 5,200 | 5,200 | |||||||||
| Compensation - officers | 2,700 | 3,600 | 11,700 | |||||||||
| Consulting | - | 12,500 | 14,500 | |||||||||
| Legal - Organization costs | - | - | 995 | |||||||||
| Other - general and administrative | 6,856 | 11,521 | 26,553 | |||||||||
| Professional fees | 36,711 | 24,883 | 69,894 | |||||||||
| Salaries | - | 36,758 | 36,758 | |||||||||
| Travel expense | - | 2,168 | 20,715 | |||||||||
| Website development cost | - | - | 19,197 | |||||||||
| Total operating expenses | 46,267 | 96,630 | 205,512 | |||||||||
| (Loss) from Operations | (39,717 | ) | (61,504 | ) | (144,683 | ) | ||||||
| Other (Income) Expenses | ||||||||||||
| Foreign currency transaction loss | 106 | 525 | 708 | |||||||||
| Total Other (Income) Expenses, net | 106 | 525 | 708 | |||||||||
| Provision for Income Taxes | - | - | - | |||||||||
| Net (Loss) | $ | (39,823 | ) | $ | (62,029 | ) | $ | (145,391 | ) | |||
| (Loss) Per Common Share: | ||||||||||||
| (Loss) per common share - Basic and Diluted | $ | - | $ | (0.01 | ) | |||||||
| Weighted Average Common Shares Outstanding: | ||||||||||||
| Basic and Diluted | $ | 10,758,137 | 9,492,685 | |||||||||
| For the Years Ended March 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenue | $ | 770,635 | $ | 463,108 | ||||
| Cost of revenues | 475,622 | 270,222 | ||||||
| Gross Profit | 295,013 | 192,886 | ||||||
| Operating Expenses: | ||||||||
| Compensation - officers | 223,404 | 260,936 | ||||||
| Officer Compensation Stock | 424,055 | 170,775 | ||||||
| Marketing | 242,719 | 332,986 | ||||||
| General and administrative | 514,467 | 653,242 | ||||||
| Donations | 35,500 | |||||||
| Loss on disposal of assets | 60,792 | |||||||
| Patent Impairment Expenses | 34,334 | |||||||
| Professional fees | 172,127 | 70,289 | ||||||
| Bad Debt Expense | 31,211 | 87,342 | ||||||
| Cost of legal proceedings | 453,553 | 79,447 | ||||||
| Research and development | 338,856 | 150,451 | ||||||
| Total operating expenses | 2,434,726 | 1,901,760 | ||||||
| Loss from operations | (2,139,713 | ) | (1,708,874 | ) | ||||
| Other Income (Expenses) | ||||||||
| Interest expense | (75,632 | ) | (4,765 | ) | ||||
| Interest income | - | |||||||
| Total other income (expenses) | (75,632 | ) | (4,765 | ) | ||||
| Net loss before income taxes | (2,215,345 | ) | (1,713,639 | ) | ||||
| Income taxes | - | - | ||||||
| Net loss | $ | (2,215,345 | ) | $ | (1,713,639 | ) | ||
| Net loss per common share: | ||||||||
| Loss per common share-Basic and Diluted | $ | (0.04 | ) | $ | (0.04 | ) | ||
EARTH SCIENC ESCIENCE TECH. INC, AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY
FOR THE YEARS ENDED MARCH 31, 2019 AND 2018
| Common Stock | Preferred Stock | Additional Paid-in | Accumalated | |||||||||||||||||||||||||
| Description | Shares | Amount | Shares | Amount | Capital | Deficit | Total | |||||||||||||||||||||
| Balance-March 31, 2017 | 42,287,499 | 42,287 | 5,200,000 | 5,200 | 23,746,430 | (23,784,568 | ) | 9,349 | ||||||||||||||||||||
| Common stock issued for cash | 3,096,698 | 3,097 | 962,895 | 965,992 | ||||||||||||||||||||||||
| Common stock issued for services | 533,010 | 533 | 447,009 | 447,542 | ||||||||||||||||||||||||
| Common stock issued for officer compensation | 233,000 | 233 | 170,542 | 170,775 | ||||||||||||||||||||||||
| Common stock issued for employee compensation | ||||||||||||||||||||||||||||
| Common stock returned to company | ||||||||||||||||||||||||||||
| Net Loss | (1,713,639 | ) | (1,713,639 | ) | ||||||||||||||||||||||||
| Balance March 31, 2018 | 46,150,207 | 46,150 | 5,200,000 | 5,200 | 25,326,876 | (25,498,207 | ) | (119,981 | ) | |||||||||||||||||||
| Common stock issued for cash | 5,180,093 | 5,180 | 1,559,014 | 1,564,194 | ||||||||||||||||||||||||
| Common stock issued for services | 75,000 | 75 | 57,345 | 57,420 | ||||||||||||||||||||||||
| Common stock issued for officer compensation | 494,500 | 495 | 423,559 | 424,054 | ||||||||||||||||||||||||
| Common stock issued for employee compensation | 30,600 | 31 | 24,052 | 24,083 | ||||||||||||||||||||||||
| Common stock returned to company | - | |||||||||||||||||||||||||||
| Common stock duplicated to be cancelled | 275,000 | 275 | (275 | ) | - | |||||||||||||||||||||||
| BCF Intrinsic value on Convertible Note-GHS | 58,916 | 58,916 | ||||||||||||||||||||||||||
| Net Loss | (2,215,345 | ) | (2,215,345 | ) | ||||||||||||||||||||||||
| Balance March 31, 2019 | 52,205,400 | $ | 52,206 | $ | 5,200,000 | $ | 5,200 | $ | 27,449,487 | $ | (27,713,552 | ) | (206,659 | ) | ||||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended March 31, 2014 | Year Ended March 31, 2013 | Cumulative From Inception (April 23, 2010) Through March 31, 2014 | ||||||||||
| Operating Activities: | ||||||||||||
| Net (loss) | $ | (39,823 | ) | $ | (62,029 | ) | $ | (145,391 | ) | |||
| Items not involving cash: | ||||||||||||
| Forgiveness of debt | ||||||||||||
| Changes in non-cash working capital: | ||||||||||||
| Change in deposits | (178,250 | ) | (178,250 | ) | ||||||||
| Change in prepaid expenses | 1,500 | |||||||||||
| Change in accounts payable and accrued liabilities | (23,798 | ) | 9,506 | 24,543 | ||||||||
| Change in advances from officers | 198,150 | 166,511 | ||||||||||
| Net Cash (Used in) Operating Activities | (43,721 | ) | (51,023 | ) | (124,182 | ) | ||||||
| Financing Activities: | ||||||||||||
| Proceeds from issuance of common stock | 376,500 | 35,800 | 419,000 | |||||||||
| Proceeds from related parties | 7,200 | 16,200 | ||||||||||
| Proceeds from loan payable-related parties | 39,169 | 1,125 | 65,686 | |||||||||
| Net Cash Provided by Financing Activities | 415,669 | 44,125 | 500,886 | |||||||||
| Net Increase (Decrease in Cash) | 371,948 | (6,898 | ) | 376,704 | ||||||||
| Cash - Beginning of Period | 4,756 | 11,654 | 0 | |||||||||
| Cash - End of Period | �� | $ | 376,704 | $ | 4,756 | $ | 376,704 | |||||
| For the Years ended March 31 | ||||||||
| 2019 | 2018 | |||||||
| Cash Flow From Operating Activities: | ||||||||
| Net loss | (2,215,345 | ) | (1,713,639 | ) | ||||
| Adjustments to reconcile net loss to net cash from operating activities: | ||||||||
| Stock-based compensation | 448,137 | 170,775 | ||||||
| Stock issued for services | 57,420 | 447,542 | ||||||
| Depreciation and amortization | 11,533 | 23,531 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Increase/Decrease in deposits | (6,190 | ) | ||||||
| Increase/Decrease in prepaid expenses and other current assets | 96,634 | 70,000 | ||||||
| Decrease/Increase in inventory | (26,525 | ) | (27,603 | ) | ||||
| Increase in other assets | - | |||||||
| Increase in accrued settlement | 7,823 | |||||||
| Increase in accounts payable | (14,878 | ) | (38,488 | ) | ||||
| Net Cash Used in Operating Activities | (1,643,024 | ) | (1,066,249 | ) | ||||
| Investing Activities: | ||||||||
| Purchases of property and equipment | ||||||||
| Patent expenditures | - | - | ||||||
| Net Cash Used in Investing Activities | - | - | ||||||
| Financing Activities: | ||||||||
| Proceeds from issuance of common stock | 1,564,194 | 965,992 | ||||||
| Proceeds from notes payable- related party | - | - | ||||||
| Proceeds from Convertible Note 1-GHS | 104,316 | |||||||
| Proceeds from Promissory Note- GHS | 30,000 | |||||||
| Repayment of advances from related party | - | - | ||||||
| Net Cash Provided by Financing Activities | 1,698,510 | 965,992 | ||||||
| Net Increase in Cash | 55,486 | (100,257 | ) | |||||
| Cash - Beginning of year | 72,038 | 172,295 | ||||||
| Cash - End of year | 127,524 | 72,038 | ||||||
| Additional | (Deficit) Accumulated | |||||||||||||||||||||||||||
| Common Stock | Paid-in | Stock | Services | Development | ||||||||||||||||||||||||
| Description | Shares | Amount | Capital | Payable | Receivable | Stage | Total | |||||||||||||||||||||
| Balance - April 23, 2010 | - | $ | - | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||||||||||
| Common stock issued for cash at $0.001 per share | 6,700,000 | 6,700 | - | - | - | - | 6,700 | |||||||||||||||||||||
| Net (loss) for the period | - | - | - | - | - | (20,687 | ) | (20,687 | ) | |||||||||||||||||||
| Balance - March 31, 2011 | 6,700,000 | 6,700 | - | - | - | (20,687 | ) | (13,987 | ) | |||||||||||||||||||
| Net (loss) for the year | - | - | - | - | - | (22,852 | ) | (22,852 | ) | |||||||||||||||||||
| Balance - March 31, 2012 | 6,700,000 | 6,700 | - | - | - | (43,539 | ) | (36,839 | ) | |||||||||||||||||||
| Common stock issued for cash at $0.01 per share | 3,580,000 | 3,580 | 32,220 | - | - | - | 35,800 | |||||||||||||||||||||
| Net (loss) for the year | - | - | - | - | - | (62,029 | ) | (62,029 | ) | |||||||||||||||||||
| Balance - March 31, 2013 | 10,280,000 | 10,280 | 32,220 | - | - | (105,568 | ) | (63,068 | ) | |||||||||||||||||||
| Forgiveness of amounts due to related party | - | - | 75,484 | - | 75,484 | |||||||||||||||||||||||
| Cash received for subscription of shares | - | - | - | 376,500 | - | 376,500 | ||||||||||||||||||||||
| Shares issued for services to be received | 700,000 | 700 | 349,300 | - | (350,000 | ) | ||||||||||||||||||||||
| Founder shares issued for services to be received | 25,000,000 | 25,000 | 12,475,000 | - | (12,500,000 | ) | ||||||||||||||||||||||
| Net (loss) for the year | - | - | - | - | - | (39,823 | ) | (39,823 | ) | |||||||||||||||||||
| Balance - March 31, 2014 | 35,980,000 | $ | 35,980 | $ | 12,932,004 | $ | 376,500 | $ | (12,850,000 | ) | $ | (145,391 | ) | $ | 349,093 | |||||||||||||
Note 1 — Organization and Nature of Operations
Earth Science Tech, Inc. (the (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010. The Company provides consulting services to the athletic facilities industry. The Company offers a full range of consulting services, including start-up strategy development, membership pricing and management, operational analysis, marketing and public relations and staff training. ESTETST is a unique biotechnology company focused on cutting edge nutraceuticals and bioceuticalsBioceuticals designed to excel in industries such as health, wellness, nutrition, supplement, cosmetic and alternative medicine to improve illnesses and the quality of life for consumers worldwide. ESTThe Company sells its products through its retail store located in Coral Gables Florida and through the internet. ETST is dedicated in providing natural alternatives to prescription medications that help improve common disorders and illnesses. EST iscurrently focused on delivering nutritional and dietary supplements that help with treating symptoms such as: chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea aging and overall wellness. This mayaging. ETSC products include products such as vitamins, minerals, herbs, botanicals, personal care products, homeopathics,homeopathies, functional foods, and other products. These products will beare marketed in various formulations and delivery forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.
Note 2 – summary— Summary of significant accounting policies
Basis of presentation
The Company’s accounting policies used in the presentation of the accompanying consolidated financial statements conform to accounting principalsprinciples generally accepted in the United States of America (“US GAAP”) and have been consistently applied.
Principles of consolidation
The accompanying consolidated financial statements include all of the accounts of the Company and its wholly-owned subsidiaries. The subsidiaries include Earth Science Tech Inc, Nutrition Empire Co. Ltd., Earth Science Vapor, and Earth Science Pharmaceutical Inc. and Kannabidioid Inc..
We operate through wholly-owned subsidiaries which provide products, marketing and distribution. As of December 2014, Nutrition Empire, Inc. was opened as a brick and mortar retail store that provides health, wellness, sports nutrition and dietary supplement products at competitive prices. In March 2015, the Company created Earth Science Tech Vapor One, Inc., a license and distribution company allowing us entry in the maturing marketplace of March 31, 2014 and 2013 and cumulative from inception. UNSI Canada is includedthe vaping industry.In 8/22/2016Earth Science Pharmaceuticals, Inc. was formed to acquire Beo Its, Inc. Our licensing relationship gives us the market mobility, allowing us to capture the emerging market offering our Cannabidiol oil to our retail partners as of September 30, 2013 and March 31, 2013 and for the period from May 6, 2010 (date of formation) through September 30, 2013.
All intercompany balances and transactions have been eliminated.
Use of estimates and assumptions
The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
The Company’s significant estimates and assumptions include the fair value of financial instruments; the accrual of the legal settlement, the carrying value recoverability and impairment, if any, of long-lived assets, including the values assigned to and the estimated useful lives of computer equipment; income tax rate, income tax provision andfixed assets; the valuation allowance of deferred tax assets; its wholly-owned subsidiary’s functional currency and foreign currency exchange rate;stock based compensation, the valuation of the inventory reserves and the assumption that the Company will continue as a going concern. Those significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to those estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.
Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.
Carrying value, recoverability and impairment of long-lived assets
The Company has adopted paragraph 360-10-35-17 of the FASBfollows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification for(“ASC’) 360 to evaluate its long-lived assets. The Company’s long-lived assets, which include officeproperty and equipment and three patent applications are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.
The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates acquired assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events.
On June 4, 2019 the Company let its patents be abandoned based upon the advice of IP counsel. IP counsel indicated that only one patent application had a reasonable chance of being granted and based upon this advice the Company determined that it would discontinue this approach of using the patent process to protect product formulations in general and rather, revert to proprietary formulae and trade secrets to protect its intellectual property (unless it was clear from the accompanying consolidated statementsbeginning of incomethe process that the formula was patentable. As a result on Jun 4, 2019, the company wrote down or otherwise impaired approximately $27,000 in legal fees that had previously been attributed to its Patents and comprehensive income (loss).
Cash and cash equivalents
The Company considers all highly liquid investments with a maturity of three months or less to be cash and cash equivalents.
Related parties
The Company follows paragraph 310-10-50-9 of the FASB Accounting Standards Codification to estimate the allowance for doubtful accounts. The Company performs on-going credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and economic conditions.
Pursuant to Section 850-10-20 the Relatedthis ASC related parties include a.a) affiliates of the Company; b. Entitiesb) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15,825-10-15, to be accounted for by the equity method by the investing entity; c.c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d.d) principal owners of the Company; e.e) management of the Company; f.f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. Otherg) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
Commitments and contingencies
The Company follows subtopic 450-20 of the FASB Accounting Standards CodificationASC 450 to report accountingaccount for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
Revenue recognition
The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codificationfollows and implemented ASC 606, Revenue from Contracts with Customers for revenue recognition. Although the new revenue standard is expected to have an immaterial effect, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities within them. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.
The Company recognizes revenue from product sales or services rendered when it is realizedcontrol of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or realizable and earned. as the Company satisfies a performance obligation.
The Company considersrecognizes its retail store revenue realizedat point of sale, net of sales tax.
Inventories
Inventories consist of various types of nutraceuticals and bioceuticals at the Company’s retail store and main office. Inventories are stated at the lower of cost or market using the first in, first out (FIFO) method. A reserve is established if necessary to reduce excess or obsolete inventories to their net realizable value.
Cost of Sales
Components of costs of sales include product costs, shipping costs to customers and earned when allany inventory adjustments.
Shipping and Handling Costs
The Company includes shipping and handling fees billed to customers as revenues and shipping and handling costs for shipments to customers as cost of revenues.
Research and development
Research and development costs are expensed as incurred. The Company’s research and development expenses relate to its engineering activities, which consist of the following criteria are met: (i) persuasive evidencedesign and development of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.
Income taxes
The Company accountsfollows ASC 740 in accounting for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferredtaxes. Deferred tax assets and liabilities are determined based on the estimated future tax effects of net operating loss carry forwards and temporary differences between the financial statement and tax bases of assets and liabilities usingand their respective financial reporting amounts measured at the current enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced byrates. The Company records a valuation allowance to the extentfor its deferred tax assets when management concludes that it is not more likely than not that thethose assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.
The Company adopted the provisions of paragraph 740-10-25-13 of the FASB Accounting Standards Codification. Paragraph 740-10-25-13 addresses the determination of whether tax benefits claimed or expected to be claimed onrecognizes a tax return should be recorded in the financial statements. Under paragraph 740-10-25-13, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.
Interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.
Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. The Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013 and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes are limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income subsequent to the ownership change.
Net income (loss)loss per common share
The Company follows ASC 260 to account for earnings per share. Basic earnings per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computedcalculations are determined by dividing net income (loss)results from operations by the weighted average number of shares of common stock outstanding during the period.year. Diluted net income (loss)loss per common share is computedcalculations are determined by dividing net income (loss)results from operations by the weighted average number of common shares ofand dilutive common share equivalents outstanding. During periods when common stock and potentially outstanding shares of common stock duringequivalents, if any, are anti-dilutive they are not considered in the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.
As of March 31 20142019 the Company has no warrants that are anti-dilutive and 2013.
Cash flows reporting
The Company adopted paragraph 230-10-45-24 of the FASB Accounting Standards Codification forfollows ASC 230 to report cash flows reporting,flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB Accounting Standards Codificationthis standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB Accounting Standards Codification.
Stock based compensation
The Company follows ASC 718 in accounting for its stock based compensation to employees. This standard states that compensation cost is measured at the guidance in Section 855-10-50grant date based on the fair value of the FASBaward and is recognized over the service period, which is usually the vesting period. The Company values stock based compensation at the market price of the Company’s common stock as of the date in which the obligation for payment of service is incurred.
The Company accounts for transactions in which service are received from non-employees in exchange for equity instruments based on the fair value of the equity instrument exchanged in accordance with ASC 505-50.
Property and equipment
Property and equipment is recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method based upon the estimated useful lives of the respective assets as follows:
| Leasehold improvements | Shorter of useful life or term of lease |
| Signage | 5 years |
| Furniture and equipment | 5 years |
| Computer equipment | 5 years |
The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from accounts and any resulting gains or losses are included in operations.
Recently issued accounting pronouncements
In August 2016, the Financial Accounting Standards CodificationBoard (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-15,Classification of Certain Cash Receipts and Cash Payments. The new standard will change the classification of certain cash payments and receipts within the cash flow statement. Specifically, payments for debt prepayment or debt extinguishment costs, including third-party costs, premiums paid, and other fees paid to lenders that are directly related to the disclosure of subsequent events.debt prepayment or debt extinguishment, excluding accrued interest, will now be classified as financing activities. Previously, these payments were classified as operating expenses. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019, with early adoption permitted, and will be applied retrospectively. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.
In February 2016, the FASB issued Accounting Standards Update No. 2016-02,Leases. This ASU requires lessees to recognize most leases on their balance sheets related to the rights and obligations created by those leases. The ASU also requires additional qualitative and quantitative disclosures related to the nature, timing and uncertainty of cash flows arising from leases. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will have on its consolidated financial statements.
In March 2016, the FASB issued Accounting Standards Update No. 2016-09,Compensation – Stock Compensation. The new standard modified several aspects of the accounting and reporting for employee share- based payments and related tax accounting impacts, including the presentation in the statements of operations and cash flows of certain tax benefits or deficiencies and employee tax withholdings, as well as the accounting for award forfeitures over the vesting period. The new standard was effective for the Company on April 1, 2017. The Company does not believe that the adoption of this new standard will have a material effect on its consolidated financial statements.
In May 2014, the financial position, resultsFASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. This guidance will supersede Topic 605, Revenue Recognition, in addition to other industry-specific guidance, once effective. The new standard requires a company to recognize revenue in a manner that depicts the transfer of operations,promised goods or cash flowsservices to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Company.
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles-Goodwill and Other, which simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. Instead, if “the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.” The guidance is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this new standard will have on its Consolidated Financial Statements.
All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.
Intangible Assets
In October 2014, the Company acquired a patent that is being amortized over its useful life of fifteen years in accordance with ASC 350, “Intangibles - Goodwill and Other”. The Company purchased the patent through a cash payment of $25,000. Additionally, the Company capitalized patent fees of $26,528. The Company’s balance of intangible assets on the condensed consolidated balance sheet net of accumulated amortizations $0 and $38,740.00 as of March 31, 2019 and March 31, 2018, respectively. Amortization expense related to the intangible assetswas$4,406.00 and $4,406.00, respectively for the years ended March 31, 2019 and 2018, respectively .For the year ended March 31, 2019 ,all patents were impaired and written off due to changes in accounting principles.$34,334 were written off to Patent impairment expenses.
Reclassification
Certain amounts from the prior period have been reclassified to conform to the current period presentation.
Note 3 – going concern
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying consolidated financial statements,At December 31, 2018, the Company had negative working capital, an accumulated deficit of $27,148,206 and was in negotiations to extend the maturity date on notes payable that are in default. These factors raise substantial doubt about the Company’s ability to continue as a deficit accumulated during the development stage at March 31, 2014, a net loss and net cash used in operating activities for the fiscal period then ended.
While the Company is attempting to generate sufficient revenues, the Company’s cash position may not be sufficient enough to pay its obligations and support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate sufficient revenues may provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate sufficient revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenues.
The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Note 4 – related party transactions (Note 7)
During 2014, a former stockholder provided funds to the Company evidenced by 8% uncollateralized notes payable due September 30, 2014. As of March 31, 2019 and March 31, 2018, the PresidentCompany had $59,558 and Chief Financial Officer$59,558, respectively of these notes payable which are in default. The Company is in current negotiations to extend the maturity of these notes for an additional 2 years. Interest expense for the twelve monthsyears ended March 31, 2014.
During the years March 31, 2019 and 2018 consulting fees were paid to Majorca Group, Ltd in the amounts of $ 0 and $ 21,776 respectively.
Kannabidioid, Inc had related party revenue from Former Stockholders
Note 5 – Stockholders’ Equity
During the years ended March 31, 2019 and 2018, the Company issued 5,180,903 and 3,096,698 common shares for cash of $1,564,194 and $965,992 respectively.
During the years ended March 31, 2019 and 2018, the Company issued 75,000 and 533,010 common shares for services at a fair value of $57,420 and $447,542 respectively.
During the years ended March 31, 2019 and 2018, the Company issued 494,500 and 233,000 common shares with a fair value of $424,054 and $170,775, respectively to officers as compensation. During the year ended March 31, 2014,2019, the PresidentCompany issued 30,600 common shares at a fair value of $24,083 to employees.
Note 6 - Commitments and Contingencies
Legal Proceedings
On January 11, 2019, the Company received notice that Strongbow Advisors, Inc., and Robert Stevens had been appointed by the Nevada District Court, as Receiver for the Registrant in Case No. A-18-784952-C.
The company sought the appointment of the Receiver after it found itself in an imminent danger of insolvency following the issuance by an arbitration panel of an award in the sum of $3,994,522.5 million in favor of Cromogen Biotechnology Corporation in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc.
The Award consisted a sum for breach of contract against the Company in the amount of $120,265, a sum for costs and fees against the Company in the amount of $111,057 and a sum for the claim of tortuous interference and conversion against the Company in the amount of $3,763,200. The District Court in Florida had confirmed the Award granted by the arbitration panel, denying however, the award of fees that the arbitration panel had granted Cromogen. (although argument has been made that only the breach of contract portion of damages should be accrued to an amount of $231,323), the Company elected not to modify the reserve previously established as “accrued settlement” until the matter is either resolved on appeal or by the receiver.
The Cromogen Litigation is now on appeal and the Company is optimistic about its prospects on appeal. Nevertheless, the outcome remains speculative and so notwithstanding its prospects for success on appeal, and faced with such a large judgment and the imminent danger of insolvency, the Company determined that it was in the best interest of its shareholders and creditors to seek protection under receivership and the appointment of a receiver. As of the date of this prospectus, the Company remains in imminent danger of insolvency as the outcome of the Cromogen Litigation remains speculative.
As part of the impact of the receivership, the Court issued a Writ of Injunction or “Blanket Stay” covering the Company and its assets during the time that the Company is in receivership. As a result of the “Blanket Stay” the Company’s estate is protected from creditors and interference with its administration is prevented while the Company’s financial issues are being fully analyzed and resolved. As part of this process, creditors will be notified and required to provide claims in writing under oath on or before the deadline stated in the notice provided by the Receiver or those claims will be barred under NRS §78.675. The Blanket Stay will remain in place unless otherwise waived by the Receiver, or it is vacated by the Court or alternatively, lifted by the Court, upon a $38,605 loan“motion to lift stay” duly made and approved by the Nevada District Court.
The appointment of the Receiver was approved unanimously by the Board and by a majority of the Company’s shareholders. Strongbow and Stevens were selected because of their reputation in helping (i) companies restructure and (ii) to execute on their business plans, albeit under a debt and capital structure that allows them to succeed. Stevens and Strongbow assist companies by helping them raise the capital needed not only to pay debts, but build and grow their businesses. The Receiver, however, is an agent of the court, and will be independent and neutral in managing the Company’s operations and trying to preserve the Company’s value for the creditors and shareholders.
There are a number of possible outcomes to the receivership, including settlement and payment to creditors, reorganization, or liquidation. The intent of the Receiver is to reorganize the Company, pay or settle the Company’s debts and emerge from receivership. If the Receiver is not successful in mitigating the Company’s liabilities, the Company’s results could be materially adversely impacted and the Company may be forced to liquidate its business.
Employment Agreement
The Company is a party to an employment agreement with its chief operations officer through October 9, 2016. The terms of the agreement requires the Company to pay its chief operations officer a monthly salary of $6,000 and 50,000 fully vested shares of the Company’s common stock at the end of each quarter. This agreement is cancelable by either party giving thirty days’ notice.
Consulting Agreement
Effective May 1, 2015, the Company entered into a Product Development and Marketing Agreement with Majorca Group, Inc. (“Developer”) a principal stockholder for cash compensation equal to 15% of certain net sales. Under the Agreement, the Company engaged Majorca to assist with the development and marketing of new product lines and to effect introductions of business prospects to the Company. The loanThis Agreement shall terminate on the 30th day of April, 2018 and is payable on 9/30/2014, is unsecured and bears interestrenewable for a second term of three years at 8%.
During the year ended March 31, 2013, the Company’s Registration Statement on the Form S-1/A filed with the Securities2019, 275,000 shares of common stock were duplicated and Exchange Commission was declared effective. The Company has sold 3,580,000 common sharesissued in error by transfer agent Island Stock Transfer and have not been cancelled yet but were recorded at $0.01 per share for total proceeds of $35,800 pursuant to this Registration Statement.
During the year ended March 31, 2014,2019 Additional Paid-in-Capital was increased by $58,916 for BCF intrinsic value of Convertible Note 1-GHS.
Commitments and Contingencies
Legal Proceedings
Cromongen Biotechnology Corporation vs. Earth Science Tech, Inc.The Company is engaged in a legal controversy with a former supplier, Cromogen Biotechnology Corporation (“Cromogen”). The controversy is a matter involving a distribution agreement and the alleged actions outside of the distribution agreement by prior management. The Company claimed that Cromogen did not perform in accordance with its contract to supply high quality hemp oil to the Company on a consistent and timely manner. In accordance with the arbitration clause stipulated to in the distribution agreement, the parties agreed to arbitrate any cotraversy arising out of the distribution agreement. Notwithstanding the fact that their agreement to arbitrate was limited to disputes arising out of the agreement, Cromogen counterclaimed damages from lost business due to prior managements’failure to forward samples of CBD oil to another potential customer of Cromogen’s, something that had not been covered by the distribution agreement. In the arbitration proceeding, the Company filed a counterclaim and affirmative defenses to Cromogen’s claims for damages. The Company also filed a legal action in the courts of Florida against Cromogen, its principals and related companies, wherein fraud is alleged in connection with Cromogen’s representations regarding the formulation and quality of the hemp oil supplied. The legal action in the Florida courts has been stayed by court order.
Since then the arbitration panel issued an award in favor of Cromogen (the “Award”) on June 8, 2018. The Award denied the Company’s counterclaims and certain of Cromogen’s claims. However, the Award was ultimately in favor of Cromogen on three issues which came in at a total of $3,994,522.55. This consisted of a sum for breach of contract against the Company in the amount of $120,265.00, a sum for costs and fees against the Company in the amount of $111,057.55 and a sum for the claim of tortuous interference and conversion against the Company in the amount of $3,763,200.00 based on alleged lost profits based on the claimed lost contract that would have allegedly resulted in business of $48 million in revenue for Cromogen. On December 17, 2018, after the issuance of a Federal Magistrate’s Report and Recommendations, the Company received notice that the District Court in Florida, had confirmed the Award that had been previously granted by the arbitration panel, denying however, the award of fees that the arbitration panel had granted Cromogen. The Company believes that the arbitration panel exceeded the scope of its authority in ruling on the tort matter on at least two grounds. First, the claim for tortuous interference and conversion do not involve the parties’ performance under the distribution agreement nor were such extra-contractual matters covered by the language in the arbitration clause. The only way to reach that conclusion is for the arbitration panel to broaden its scope to include them. As such, it is the Company’s position that the arbitration panel exceeded the scope of its authority in hearing and ruling on the tort claims. Second, as a matter of law, the allowance of the tort claims violates the economic loss principles in contract law in the State of New York; and because of the forgoing reasons, among others, the court erred in failing to vacate the tort portions of the Award. This matter is now on appeal and the Company is optimistic about its prospects on appeal because of several recent cases in the jurisdiction where lower courts’ judgments confirming arbitration awards have been overturned because the arbitrators exceeded the scope of their authority.
Notwithstanding its prospects for success on appeal, faced with such a large judgment, the Company considered its options and settled on the appointment of a receiver and putting the Company into receivership. On January 11, 2019 the Company received notice that Strongbow Advisors, Inc., and Robert Stevens (the “Receiver”) had been appointed as receiver by the Nevada District Court, Clark County Nevada in Case No. A-18-784952-C. In addition to appointing the Receiver, the Court issued a Writ of Injunction or “Blanket Stay” covering the Company and its assets during the time that the Company is in receivership. The Blanket Stay will remain in place unless otherwise waived by the Receiver, or it is vacated by the Court or alternatively, lifted by the Court, upon a “motion to lift stay” duly made and approved by the Nevada District Court. The purpose of the “Blanket Stay” is to protect the estate and prevent interference with its administration while the Company’s financial issues are fully analyzed and resolved. As part of this process, creditors will be notified and required to provide claims in writing under oath on or before the deadline stated in the notice provided by the Receiver or those claims will be barred under NRS §78.675.
The Registrant determined that it was in its best interest and those of its shareholders and creditors to seek protection under receivership after evaluating its options following the order for judgment in favor of Cromogen in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc.. The appointment of Strongbow Advisors, Inc. and Robert Stevens as Receiver was approved unanimously by the Registrant’s Board of Directors and a majority of its debt holders. Strongbow and Stevens were selected because of their reputation of helping companies restructure and continue to execute on their business plans, albeit under a debt and capital structure that allows them to succeed. Unlike many receivers who simply look to wind up the affairs of a company and liquidate its assets, Stevens and Strongbow have built a reputation and differentiated themselves by assisting companies with financings and working in the capital markets to help companies raise the capital needed not only to pay debts but to build and grow their businesses. As a result, they are almost hyper-vigilant in protecting their companies’ shareholders and are not focused solely on creditors.
About Strongbow Advisors, Inc.
After lengthy discussions with its principal, Robert Stevens, and after having had an opportunity to research the history of some of the companies for which he and his firm were judicially appointed as receiver, Earth Science’s management is optimistic about having Strongbow Advisors serve as its Receiver. As stated, unlike many receivers who take a liquidation approach to their judicial roles, Stevens has a pragmatic philosophy of helping companies to restructure and use, what is generally considered, a negative situation as an opportunity for them to become better, stronger, more vibrant, operating companies. Stevens has a firm commitment to protecting creditors and shareholders alike; however, it’s his attention to an enterprise as a whole and in particular on the business’ shareholders that truly differentiates Strongbow Advisors and him from other receivers.
In his role as receiver, Stevens has reorganized companies that emerge from receivership having fully settled all of their liabilities and recovered significant value for their shareholders, to continue as stronger successful companies. As an example, in one case we reviewed, while in receivership the company was not only able to raise capital and pay its creditors in full, it was also able to recover all of the value for the investing shareholders dating back to its IPO in 2008; and in that case, those IPO investors had not only not lost money, but were able to realize substantial returns on their investments as shareholders.
In short, Stevens has a breadth of experience as a receiver helping companies and their creditors, shareholders and other constituents who have effectively “found themselves with lemons,” to “make high quality lemonade.” As such Earth Science is optimistic that it will be another one of Strongbow’s success stories.
Lease Agreements
On August 14, 2017, the Company entered into an office lease covering its new Doral, Florida headquarters, with landlord Doral Flex. The Lease term is for 37 months commencing on September 1, 2017 and ending on September 30, 2020. The monthly rent, including sales tax is $1,990, $2,056 and $2,124 for the years ending 9/30/2018, 9/30/2019 and 9/30/2020 respectively. A deposit of $6,191 was tendered to secure the lease. Rent expense for the three months and nine months ended December 31, 2018 were $6,996 and $20,218 respectively.
| F-16 |
Note 7 - Balance Sheet and Income Statement Footnotes
Accounts receivable represent normal trade obligations from customers that are subject to normal trade collection terms, without discounts or rebates. If collection is expected in one year or less they are classified as current assets. If not, they are presented as non-current assets. Notwithstanding, these collections, the Company periodically evaluates the collectability of accounts receivable and considers the need to establish an allowance for doubtful debts based upon historical collection experience and specifically identifiable information about its customers. As of March 31, 2019 and 2018, the Company had sold 753,000 common shares at $0.50 per shareallowances of $128,420 and $111,301 respectively. The Company used an allowance of 40% of receivables over 90 days to charge bad debt expense.
Prepaid expenses and other current assets for total proceeds of $376,500. The 753,000 common shares were issued after$33,751 for the year ended March 31, 2014.
Accounts payable are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities
Accrued expenses of $85,440 as of March 31, 20142019 represent $25,440 of accrued interest on notes payable and accrued payroll for Michael Aube for $60,000.
Promissory Note-GHS was 208,000initiated 2/28/19 for $142,250.
Convertible Note 1-GHS issued 2/13/19 for cash received $103,000, face amount $113,300 will accrue at a rate of 10% on a 360-day year. Maturity date is November 13,2019.
Marketing expenses were $ 242,719 and $332,986 for March 31, 2019 and 2018 respectively.
General and administrative expenses were $514,467 and $653,242 for March 31, 2019 and 2018 respectively. For the period March 31, 2019, the majority comprised of consulting fees in the amount of $188,889, employee compensation of $74,322 and accounting and audit fees of $77,396. The remainder, $173,860 was for rent, event expenses and other expenses.
Professional fees were $172,127 and $106,289 for years ended March 31, 2019 and 2018, respectively. The bulk of these expenses were paid to transfer agent for issuance of stock for $16,187, Strongbow Advisors for $73,547, GHS for $30,000 and OTC Markets for $16,000 for the year ended March 31, 2019.
Research and development were $338,856 and $150,451 for years ending March 31, 2019 and 2018.These expenses were for further development of medical device.
Interest expense was $75,632 and $4,765 for years ended March 31, 2019 and 2018, $70,664 was for Convertible Note 1-GHS.
Note 8-Subsequent Events
On June 6, 2014January 1, 2019 the Company filedengaged David Barbash as chief sales officer (“CSO”) transitioning Jill Buzan, the Company’s previous CSO, to the position as a Florida sales representative.
On January 11, 2019 the Company signed an agreement to transfer of majority ownership and control of its wholly owned subsidiary, Kannabinoid, Inc., to a third party, retaining an interest in an ongoing 5% royalty on all sales of its Kana product.
On January 09, 2019 the Company entered into receivership with the Statejudicial appointment of Nevada ArticlesRobert Stevens and Strongbow Advisors, Inc. The Company determined that it was in its best interest and those of Amendment creatingits shareholders and creditors to seek protection under receivership after evaluating its options following the order for judgment in favor of Cromogen in the matter entitled Cromogen Biotechnology Corporation vs. Earth Science Tech, Inc.. The appointment of Strongbow Advisors, Inc. and Robert Stevens as Receiver was approved unanimously by the Registrant’s Board of Directors and a Preferred A classmajority of stockits debt holders. Strongbow and Stevens were selected because of their reputation of helping companies restructure and continue to execute on their business plans, albeit under a debt and capital structure that allows them to succeed. Unlike many receivers who simply look to wind up the affairs of a company and liquidate its assets, Stevens and Strongbow have built a reputation and differentiated themselves by assisting companies with 10,000,000 Preferred A shares havingfinancings and working in the capital markets to help companies raise the capital needed not only to pay debts but to build and grow their businesses. As a par value of $0.001 per share.
EVALUATION OF DISCLOSURE CONTROLS & PROCEDURES
Our management is responsible for establishing and procedures as of the end of the 2014 fiscal year. This evaluation was conducted with the participation of our chief executive officer and our principal accounting officer.
●Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
● Provide reasonable assurance that transactions are recorded processed, summarizedas necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and reported.
● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Effectivefinancial statements.
Because of Controls
The Company’s management assessed the effectiveness of the inherent limitationsCompany’s internal control over financial reporting as of March 31, 2019. In making this assessment, the Company’s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission 1992 (“COSO”) in a cost-effectiveInternal Control-Integrated Framework. The COSO framework is based upon five integrated components of control: control system, misstatements due to error or fraud may occurenvironment, risk assessment, control activities, information and may not be detected.
Based upon theiron an evaluation under the supervision and with the participation of our controls, the chiefCompany’s management, the Company’s principal executive officer and principal accountingfinancial officer havehas concluded that subjectthe Company’s internal control over financial reporting as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were not effective as of March 31, 2019 (the “Evaluation Date”), to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the limitations notedCompany’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Each of the following is deemed a material weakness in our internal control over financial reporting:
● Limited or no segregation of duties and lack of multiple levels of supervision and review.
● No independent directors.
● Ineffective controls over financial reporting.
● Lack of controls over authorization related party transactions.
Management believes that the material weaknesses set forth in the four items above did not have an effect on our financial results. However, management believes that the disclosurelack of a functioning audit committee results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.
Management’s Remediation Initiatives
In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we plan to initiate the following series of measures once we have the financial resources to do so:
We expect to create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are effective providing reasonable assuranceavailable to us. And, we plan to appoint one or more outside directors to an audit committee resulting in a fully functioning audit committee, which will undertake the oversight in the establishment and monitoring of required internal controls and procedures, such as reviewing and approving estimates and assumptions made by management when funds are available to us.
Management believes that material information relatingthe appointment of outside directors to us is made known to management on a timely basis duringfully functioning audit committee, would remedy the period when our reports are being prepared. lack of a functioning audit committee.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal controls over financial reporting that occurred during the yearperiod covered by this report, which were identified in connection with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal controls.
This Annual Report does not include an attestation report of the Company’s registered independent public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report in this Annual Report.
None
Item 10. Directors, Executive Officers and Corporate Governance.
The following table presents information with respectCompany does not, at present, have any employees other than the current officers and directors. We have not entered into any employment agreements, as we currently do not have any employees other than the current officers and directors.
Directors and Executive Officers
| Name | Principal Occupation | Age | Director or Officer Since | |||||||
| Nickolas S. Tabraue | President, Secretary Director, Chairman of the Board | 31 | 2015 | |||||||
| Steve Warm | Director and Chief Legal Counsel | 76 | 2017 | |||||||
| Gagan Hunter | Chief Operating Officer and Director | 60 | 2018 | |||||||
| Dr. Michel Aube | Chief Executive Officer and Chief Science Officer | 50 | 2016 | |||||||
| Wendell Hecker | Chief Financial Officer | 63 | 2018 | |||||||
| Sergio Castillo | Chief Marketing Officer | 35 | 2017 | |||||||
| David Barbash | Chief Sales Officer | 53 | 2019 | |||||||
| Robert Stevens | Court Appointed Receiver | 53 | 2019 | |||||||
There are no other persons nominated or chosen to ourbecome directors or executive officers, nor do we have any employees other than above mentioned officers and directors.
Our directors and significant employees as ofhold office until the date of this Report:
Officer and Director Background:
Nickolas S. Tabraue - President, Director, & Chairman
Mr. Tabraue is an industry veteran having 13 years of Directors.
Robert Stevens - Appointed Receiver
Mr. Stevens has more than 30 years of experience in the securities and finance industries. Mr. Stevens is president of Somerset Capital Ltd (“Somerset”) which he founded in 2001 and he serves until his or her successoras president and managing director. Somerset is electeda private capital firm that employs industry-specific skillsets to make strategic investments in distressed and qualified. Eachturnaround situations as well as merger and direct investments in private and pre-public companies. Mr. Stevens is also president of our officersStrongbow Advisors, Inc., which provides turnaround and receiver advisory as well as consulting services. Mr. Stevens also serves as a court - appointed receiver. Mr. Stevens was also Managing Director of Technology Partners, a private equity and M&A firm from 2006 to 2013. Mr. Stevens is elected bycurrently an independent director for from Social Enterprises (OTCQB: GRMM) where he serves as chair of the audit committee, and has also served on the board of directorsAppTech Corp (OTC: APCX) from July 2016 to March of 2017.
Steve Warm, Esq. - Director & Chief Legal Counsel
Mr. Warm was born in New York City and grew up in Northern New Jersey. He is a termgraduate of one (1) yearDickinson University (Teaneck, N.J.) and serves untilRutgers University Law School (Newark, N.J.). Mr. Warm finished law school at the age of 21 and sat for the New Jersey Bar only a few weeks after his or her successor22nd birthday. (He is duly electedbelieved to be the youngest person to have been admitted to practice in New Jersey once a law school degree became a prerequisite). After practicing in Ramsey, New Jersey, Burlington, New Jersey., Willingboro, New Jersey and qualified, or until he or she is removed from office. At the present time, membersMedford, New Jersey, Mr. Warm became a member of the Florida Bar, practicing exclusively in Boca Raton for 25 years. In 1986, he joined his three sons in Gainesville, Florida, where he presently maintains his primary office, although he still has and uses facilities in Boca for specific clients. Mr. Warm has experience in diverse areas of the law over a lengthy span of years. He has done tax work, corporate representation, entrepreneurial support, litigation, and family law, contractual issues of all kinds, personal injury matters, estate planning/probate and many other things. Mr. Warm has successfully represented any number of companies, large and small, domestic and foreign, public and private. He was instrumental in obtaining the seminal Federal Court ruling which paved the way for the expansion of national banks. In evaluating Mr. Warm’s specific experience, qualifications, attributes and skills in connection with his appointment to our board, we took into account his experience in various areas of directors are not compensated for their services to the board.
Dr. KatzMichel Aube - CEO & Chief Science Officer (CSO)
Dr. Aubé has wide-ranging expertise in the life sciences. As a microbiologist he furthered his graduate studies at Laval University, earning a Master’s degree in Cell Biology and Molecular Physiology as well as a PhD in EnvironmentalPhysiology-Endocrinology. Prior to joining Earth Science from 2008-2010 he served as a MastersPost-doc Researcher in Immunology at the University of Business ManagementMontreal where he was responsible for the development of a therapeutic vaccine to treat AIDS based on ex-vivo maturation of dndritic cells from patients. Thereafter, in 2010, he was a post-doc researcher conducting fundamental research to understand the role of the genes implicated in the maturation of T cells, and Bachelors in Business Administration.2012 his research was focused on understanding the mechanism of action of a new drug that improves the graft versus host disease in patients that received hematopoietic stem cell transplants. Following his post-doc research at the University of Montreal in 2013 he founded BOE, ITS with the objective of developing the company’s MSN-2 medical device for the treatment of Sexually Transmitted Infections. In addition, he created and taught three postdoctoral courses in Immunology. His scientific research in Sexually Transmitted Infections (STIs), Cancer and Stem Cell biology has been published in several prestigious medical journals. Dr. Aubé has received a number of Awards for Excellence from the Network for environmental health research and childhood diseases.
Wendell Hecker - CFO
Mr. Hecker earned a Bachelor of Science in Accounting from New York University. Having spent more than 30 years at large corporations in New York and Florida, he brings to Earth Science Tech, extensive accounting experience. Prior to joining Earth Science Mr. Hecker was the Controller for Ampco Electric, Inc. where he was in charge of all accounting operations. Before joining Ampco in 2014 he was self-employed as an accountant serving a variety of clients and meeting their accounting needs and prior to starting his own accounting practice from 2007 through 2010 he served as the controller of Seaview Research Inc., Hecker will ensure that the Company’s accounting follows best practices, keeps up-to-date, and increases transparency with investors as sales continue to increase.
Sergio Castillo - Chief Marketing Officer (CMO)
Mr. Castillo joined the Company as its Chief Marketing Officer in January 2017. He moved to Miami when he was only 16, is a current marketing consultant for few firms including Cloud Accounting, La Familia Media, Fresh Press Miami, Goodlife Miami, as well as Abdon Entertainment. He started his first company in 2008 called “Goodlife Miami, LLC”. In 2010, his second company was started named Fresh Press, LLC. His third company, which he still owns and operates, was founded in 2012, called La Familia Media, LLC. As an entrepreneur, Dr. Katzthe time passed, he has held leadershiplearned what is necessary to run the marketing plans for many successful companies, and he is taking his expertise into the field of industrial based hemp and hemp products. At each of his companies and currently with Earth Science, Mr. Castillo handles graphics, web design, and marketing. As the CMO of Earth Science Tech, Inc he is in a position to bring his experience to the new and fast moving industry that is developing around hemp and hemp products.
David Barbash - Chief Sales Officer (CSO)
Brings in 20 years of natural products industry experience in both the U.S. and U.K. markets having worked with niche forward thinking companies at the time like, Health From The Sun/Arkopharma, Pure Essence Labs, and Harmonic Innerprizes. Mr. Barbash is highly skilled in strategic sales planning, team development, analytic reasoning, business development, new product launch, market analysis, training design and development, and brings international experience to the Company
Gagan Hunter - Director & COO
Mr. Hunter a graduate from Oaksterdam University, America’s first primer cannabis college, University of Pittsburgh, and post graduate studies at the Temple University, Gagan Hunter is a holistic health specialist, cannabis & cannabinoid (CBD) educator. Mr. Hunter has 20 years of natural products industry experience in sales, marketing, and management, rolesand 20 years teaching nutrition. Prior to joining Earth Science Mr. Hunter worked for Mother Earth’s County, representing over 250 manufacturers of natural products and supplements to retailers such as Whole Foods, Earth Fare and Sprouts, throughout North and South Carolina Georgia and Tennessee. He was responsible for product placement, product training, consumer education, demonstrations and merchandising. He was also responsible for staff training, purchasing, customer service, budgets, sales reporting, conducting sales meetings, setting sales goals, tracking store inventories and financial management throughout his 16 years at Mother Earth’s Bounty. His skills obtained through his 20 years in several companiesthe industry are staff training, purchasing, customer service, inventory control, and served as Chief Executive Officer of International Foam Solutions, Inc. (a recycling chemicalfinancial management. In evaluating Mr. Hunter’s specific experience, qualifications, attributes and equipment manufacturer)skills in that capacity, he developed the company’s marketing and strategic plans and oversaw the manufacturing operations. He started and developed International Foam Solutions, a recycling and manufacturing company. The company went public in 1999 and Dr. Katz was president of the company. Duringconnection with his tenure as president of IFS, the company never had any shareholder suits of any kind.
Committees of Florida (Gainesville), UNLV, Virginia Tech, and Reynolds Tobacco Corp. on polystyrene recycling.
The Company is managed under the direction of ethics that applies to our principal executive officers, principal financial officer, principal accounting officer or controller, or persons performing similar functions, since we have been focusing our efforts on obtaining financing for the company. We expect to adopt a code by the end of the current fiscal year.
| (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) |
| Change in | |||||||||
| Pension | |||||||||
| Value & | |||||||||
| Non-Equity | Non-quali- fied | ||||||||
| Incentive | Deferred | All | |||||||
| Plan | Compen- | Other | |||||||
| Stock | Option | Compen- | sation | Compen- | |||||
| Name and Principal | Salary | Bonus | Awards | Awards | sation | Earnings | sation | Totals | |
| Position [1] | Year | ($)* | ($) | ($) | ($) | (S) | ($) | ($)* | ($) |
| Larissa Zabelina | 2013 | 0 | 0 | 0 | 0 | 0 | 0 | 3,600 | 3,600 |
| President, CEO | 2012 | 0 | 0 | 0 | 0 | 0 | 0 | 3,600 | 3,600 |
| Elena Mochkina, CFO, | 2013 | 0 | 0 | 0 | 0 | 0 | 0 | 3,600 | 3,600 |
| Treasurer, Secretary | 2012 | 0 | 0 | 0 | 0 | 0 | 0 | 3,600 | 3,600 |
The Company does not maintainhave an executive committee, at this time.
The Company does not have an audit committee at this time.
Officer’s and Director’s Involvement in Legal Proceedings
No executive Officer or Director of the Company has been convicted in any qualified retirement planscriminal proceeding (excluding traffic violations) or non-nonqualified deferred compensation plans for its employeesis the subject of a criminal proceeding that is currently pending. No executive Officer or directors.
| Name of Beneficial Owner | Amount and Nature of Beneficial Ownership | Percentage of Beneficial Ownership | |
| Title of Class | Directors and Officers: | (1) | % |
| Common | Harvey Katz, CEO, President and Director | 0 | 0 |
| Common | All executive officers and directors as a group (2 persons) | 6,700,000 | 18% |
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Stock Awards ($) | Non-Equity Incentive Plan Compensation ($) | All Other Compensation ($) | Total ($) | ||||||||||||||||||||
| Nickolas S. Tabraue, | 2019 | 104,000 | — | 172,000 | (1) | — | — | 276,00.00 | |||||||||||||||||||
| President, Secretary & Director | 2018 | 102,500 | — | 138,000 | (2) | — | — | 240,500.00 | |||||||||||||||||||
| Dr. Michel Aube, | 2019 | 48,000 | — | 172,000 | (1) | — | — | 220,000.00 | |||||||||||||||||||
| Chief Executive Officer | 2018 | 72,000.15 | — | 228,000 | (3) | — | — | 300,000.15 | |||||||||||||||||||
| Wendell Hecker | 2019 | 30,500.05 | — | 34,400 | (4) | — | — | 64,900.05 | |||||||||||||||||||
| Chief Financial Officer | 2018 | 4,615.40 | — | 7,100 | (5) | — | — | 11,715.40 | |||||||||||||||||||
| Jill Buzan | 2019 | 53,795.37 | — | 7,413 | (6) | — | — | 61,208.37 | |||||||||||||||||||
| Chief Sales Officer | 2018 | 7,936.87 | — | 1,775 | (7) | — | — | 9,711.87 | |||||||||||||||||||
| Gagan Hunter | 2019 | 69,923.05 | — | 34,400 | (4) | — | — | 104,323.05 | |||||||||||||||||||
| Chief Operating Officer | 2018 | 2,076.92 | — | 7,100 | (4) | — | — | 9,176.92 | |||||||||||||||||||
| (1) | During the fiscal year ended March 31, | 2019, as compensation for services rendered, was issued: (i) 50,000 shares of common stock, at a price of $0.80 per share; (ii) 50,000 shares of common stock, at a price of $1.26 per share; (iii) 50,000 shares of common stock, at a price of $0.79 per share; and (iv) 50,000 shares of common stock, at a price of $0.59 per share. | |||||||
| (2) | During the fiscal year ended March 31, 2018, as compensation for services rendered, was issued: (i) 50,000 shares of common stock, at a price of $0.80 per share; (ii) 50,000 shares of common stock, at a price of $0.54 per share; and (iii) 50,000 shares of common stock, at a price of $1.42 per share. | ||||||||
| During the fiscal year ended March 31, 2018, as compensation for services rendered, was issued: (i) 100,000 shares of common stock, at a price of $0.90 per share; (ii) 50,000 shares of common stock, at a price of $0.80 per share; (iii) 50,000 shares of common stock, at a price of $0.54 per share; and (iv) 50,000 shares of common stock, at a price of $1.42 per share. | |||||||||
| During the fiscal year ended March 31, 2019, as compensation for services rendered, was issued: (i) 10,000 shares of | common stock, at a price of $0.80 per share; (ii) 10,000 shares of common stock, at a price of $1.26 per share; (iii) 10,000 shares of common stock, at a price of $0.79 per share; and (iv) 10,000 shares of common stock, at a price of $0.59 per share. | ||||||||
| During the fiscal year ended March 31, 2018, as compensation | for services rendered, was issued 10,000 shares of common stock, at a price of $0.71 per share. | ||||||||
| (6) | During the fiscal year ended March 31, 2019, as compensation for services rendered, was issued: (i) 400 shares of common stock, at a price of $0.72 per share; (ii) 2,500 shares of common stock, at a price of $1.26 per share; (iii) 2,500 shares of common stock, at a price of $0.79 per share; and (iv) 2,500 shares of common stock, at a price of $0.80 per share. | ||||||||
| (7) | During the fiscal year ended March 31, 2018, as compensation for services rendered, was issued 2,500 shares of common stock, at a price of $0.71 per share. | ||||||||
EMPLOYMENT AGREEMENTS
Nickolas S. Tabraue started in 2015 at a base salary of $5,000 per month and 50,000 shares granted per quarter. This was changed to $6,000 per month in the first quarter of 2016 and then to $7,000 in the fourth quarter of 2016 and finally to $4,000 every two weeks in the second quarter of 2017. On March 19, 2018 the Company entered into an Employment Agreement with Mr. Tabraue (the “Tabraue Employment Agreement”) for a term of 1 year, renewable upon mutual agreement of both parties for an additional 1 year term. The Tabraue Employment Agreement provides that Mr. Tabraue receive a $8,666.00 monthly salary and 50,000 shares each fiscal quarter. The Tabraue Employment Agreement may be terminated with or without cause, pursuant to the terms therein.
Wendell Hecker and the Company entered into an employment agreement on February 1, 2018 (the “Hecker Employment Agreement”). The Hecker Employment Agreement provides that Mr. Hecker is to receive a salary of $2,500 per month and 10,000 shares of restricted common stock per quarter. The term of the Hecker Employment Agreement is 1 year, renewable upon mutual agreement of both parties for an additional 1 year term. The Hecker Employment Agreement may be terminated with or without cause, pursuant to the terms therein.
Sergio Castillo and the Company entered into an employment agreement on January 24, 2017 (the “Castillo Employment Agreement”). The Castillo Employment Agreement provides that Mr. Hecker is to receive a salary of $750 per month. The term of the Hecker Employment Agreement is 6 months, renewable upon mutual agreement of both parties for an additional 6 month term. The Castillo Employment Agreement is still in effect. The Castillo Employment Agreement may be terminated with or without cause, pursuant to the terms therein.
Gagan Hunter and the Company entered into an employment agreement on March 20, 2018 (the “Hunter Employment Agreement”). The Hunter Employment Agreement provides that Mr. Hunter received a $4,500 per month salary which was subsequently increased to $6,000 per month in the second quarter of 2018. Additionally, he receives 10,000 shares of restricted common stock per quarter. The term of the Hunter Employment Agreement is 1 year, renewable upon mutual agreement of both parties for an additional 1 year term. The Hunter Employment Agreement may be terminated with or without cause, pursuant to the terms therein.
Dr. Michel Aube started in August 2016 at a base salary of $6,000 per month and 50,000 shares of restricted common stock granted per quarter.
David Barbash and the Company entered into an employment agreement on January 1, 2019 (the “Barbash Employment Agreement”). The Barbash Employment Agreement provides that Mr. Barbash is to receive a salary of $4,000 per month, 12.5% commission from all his sales, plus 5% commission from all sales through representatives managed by Mr. Barbash, along with 5,000 shares of the common stock per quarter. Mr. Barbash has a three month probation period and based on his performance the company may decide to keep and relinquish Mr. Barbash.
The compensation that is listed in the table above does not necessarily correspond directly to the officers’ employment agreements for a number of reasons. For example, Dr. Aube’s compensation does not show a full $72,000 in 2017 because payment didn’t actually begin until part way through the year. In other cases such as Gabriel Aviles, he was not an officer until later, after joining the Company so there may have been compensation re received in his position as a sales person that had been paid to him. In other cases there may be increases in salary that have not been formally reflected by amending employment agreements, rather the board of directors or the President, in the case of officers who report directly to the President, may have increased salaries during the year due to outstanding performance and increased work load. The table above reflects what these officers and directors have actually received for their service as officers and directors during the applicable time period and both the Company and the officers and directors have agreed to the amount of compensation paid.
Mr. Barbash entered into an employment agreement with the Company for a term of one (1) year and is renewable for a period of one (1) additional year upon mutual agreement by the parties. Mr. Barbash’s compensation for the term is four thousand dollars (US$4,000) per month together with commission from all sales through the Chief Sales Officer of twelve and one half percent (12%) as well as five percent (5%) percent commission from all sales through the representatives under him per month, to commence on the date of this agreement during the first three months. After the first three months he will be entitled to receive a monthly base of five thousand dollars (US$5,000.00) per month in addition to the forgoing commission structure. The frequency of monthly payments and paid commissions shall be paid on the 15th (fifteen) of each month. In addition, the Chief Sales Officer will be entitled to 5,000 shares each fiscal quarter. Moreover, the board of directors of the company (majority vote) may from time to time, based on the Chief Sales Officer’s performance, compensate the executive in additional forms of cash and or stock bonus, in their discretion. Additionally, all preapproved business travel expenses will be paid by the Company: (e.g. airfare, hotel, car rental, meals, tolls, taxi fares if necessary or train or ferry fare, cell phone, email, copies and approved pertinent office supplies.)
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE-IN-CONTROL
SEC regulations state that we must disclose information regarding agreements, plans or arrangements that provide for payments or benefits to our executive officers in connection with any transactionstermination of employment or change in control of the Company. Such payments are set forth above in the section entitled “Employment Agreements.”
None of our executive officers or directors received, nor do we have any arrangements to pay out, any bonus, stock awards, option awards, non-equity incentive plan compensation, or non-qualified deferred compensation.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END
None.
OPTION/SAR GRANTS IN THE LAST FISCAL YEAR
None.
CONSULTING AGREEMENTS WITH OFFICERS AND DIRECTORS
None.
DIRECTOR COMPENSATION
All of the Company’s officers and/or directors will continue to be active in other companies. All officers and directors have retained the right to conduct their own independent business interests.
The Company does not pay any Directors fees for meeting attendance.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Company’s officers and directors are indemnified as provided by the Nevada Revised Statutes and the bylaws.
Under the Nevada Revised Statutes, director immunity from liability to a company or its shareholders for monetary liabilities applies automatically unless it is specifically limited by a company’s Articles of Incorporation. The Company’s Articles of Incorporation do not specifically limit the directors’ immunity. Excepted from that immunity are: (a) The director’s or officer’s act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and (b) The breach of those duties involved intentional misconduct, fraud or a knowing violation of law.
The Company’s bylaws provide that it will advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer of the Company, or is or was serving at the request of Earth Science Tech as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefore, all expenses incurred by any director or officer in connection with such proceeding upon receipt of an undertaking by or on behalf of such person to repay said amounts if it should be determined ultimately that such person is not entitled to be indemnified under the bylaws or otherwise.
OTHER
In May, 2018, our Chief Sales Officer and Director, Gabriel Aviles departed and the Company thanked him for his service.
On January 1, 2019 the Company engaged David Barbash as chief sales officer (“CSO”) transitioning Jill Buzan, the Company’s previous CSO, to the position as a Florida sales representative.
There are no other employment agreements between the Company and its executive officers or directors. Our executive officers and directors has the responsibility of determining the timing of remuneration programs for key personnel based upon such factors as positive cash flow, shares sales, product sales, estimated cash expenditures, accounts receivable, accounts payable, notes payable, and a cash balances. At this time, management cannot accurately estimate when sufficient revenues will occur to implement this compensation, or the exact amount of compensation.
There are no annuity, pension or retirement benefits proposed to be paid to officers, directors persons nominated for these positions,or employees of the corporation in the event of retirement at normal retirement date pursuant to any presently existing plan provided or contributed to by Company.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The following table sets forth certain information with respect to the beneficial owners of 5% or moreownership of our common stock, or family membersshares as it relates to our named directors and executive officers, and each person known to the Company to be the beneficial owner of these persons wherein the amount involved in the transaction or a seriesmore than five percent (5%) of similar transactions exceeded $60,000.
Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock and options, warrants and convertible securities that are currently exercisable or convertible within 60 days of the date of this document into shares of the Company’s common stock are deemed to be outstanding and to be beneficially owned by the person holding the options, warrants or convertible securities for the purpose of computing the percentage ownership of the person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.
The information below is based on the number of shares of the Company’s common stock that we believe was beneficially owned by each person or entity as of June 25, 2019.
| Beneficial Owner | Common Stock | Series A Preferred Stock | Number of Shares Beneficially Owned | Percent | ||||||||||||
| 5% Stockholders: | ||||||||||||||||
| Majorca Group, Ltd. | 24,520,000 | 5,200,000 | 29,720,000 | 56.978 | % | |||||||||||
| Great Lakes Holdings Group, Inc. | 6,700,000 | 6,700,000 | 12.844 | % | ||||||||||||
| Named Executive Officers and Directors: | ||||||||||||||||
| Michel Aube - Chief Executive Officer and Chief Science Officer | 518,500 | 518,500 | 0.994 | % | ||||||||||||
| Nickolas S. Tabraue – President, Secretary and Director (former Chief Operating Officer) | 900,000 | 900,000 | 1.725 | % | ||||||||||||
| Steven Warm, Chief Counsel and Director | 14,500 | 14,500 | 0.027 | % | ||||||||||||
| Wendell Hecker, Chief Financial Officer | 50,000 | 50,000 | 0.096 | % | ||||||||||||
| Sergio Castillo, Chief Marketing Officer | 0 | 0 | 0 | |||||||||||||
| David Barbash, Chief Sales Officer | 7,000 | 7,000 | 0.013 | % | ||||||||||||
| Gagan Hunter, Chief Operating Officer | 50,000 | 50,000 | 0.096 | % | ||||||||||||
| All executive officers and directors as a group (8 persons) | 1,540,000 | 2.951 | % | |||||||||||||
*The Address for the above individuals is c/o 8000 NW 31st Street Unit 19, Doral, FL 33122.
(1) Based on 52,160,400 common shares outstanding as of June 25, 2019.
Rule 13d-3 under the Securities Exchange Act of 1934 governs the determination of beneficial ownership of securities. That rule provides that a beneficial owner of a security includes any person who directly or indirectly has or shares voting power and/or investment power with respect to such security. Rule 13d-3 also provides that a beneficial owner of a security includes any person who has the right to acquire beneficial ownership of such security within sixty days, including through the exercise of any option, warrant or conversion of a security. Any securities not outstanding which are subject to such options, warrants or conversion privileges are deemed to be outstanding for the purpose of computing the percentage of outstanding securities of the class owned by such person. Those securities are not deemed to be outstanding for the purpose of computing the percentage of the class owned by any other person.
There were no grants of stock options since inception to March 31, 2019. We do not have any long-term incentive plans that provide compensation intended to serve as incentive for performance.
The Board of Directors of the Company has not adopted a stock option plan. The company has no plans to adopt it but may choose to do so in the future. If such a conflict will disclose her interestplan is adopted, this may be administered by the board or a committee appointed by the board (the “Committee”). The committee would have the power to modify, extend or renew outstanding options and to authorize the grant of new options in a proposed transactionsubstitution therefore, provided that any such action may not impair any rights under any option previously granted. The Company may develop an incentive based stock option plan for its officers and will abstain from voting for or against the approvaldirectors and may reserve up to 10% of such transaction.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
During 2014, a former stockholder provided funds to the Company evidenced by 8% uncollateralized notes payable due September 30, 2014. As of March 31, 2019, and March 31, 2018, the Company had $59,558 and $59,558, respectively of these notes payable which are in default. The Company is quoted onin current negotiations to extend the OTC bulletin board interdealer quotation system, which does not have director independence requirements. Under NASDAQ rule 4200(a)(15), a director is not considered to be independent if he or she is alsomaturity of these notes for an executive officer or employee of the corporation. Our director, Harvey Katz, is also our chief executive officer; our director Harvey Katz is also our chief financial officer. As a result, none of our directors is independent.
During the years March 31, 2019 and 2018 consulting fees were paid to Majorca Group, Ltd in the amounts of Las Vegas, Nevada to handle all$ 0 and $ 21,776 respectively.
Kannabidioid, Inc had related party revenue from Earth Science Tech Inc in the amount of our accounting. During$540 for the year ended March 31, 2013 we engaged Ronald R. Chadwick, P.C.2019.
EQUITY ISSUANCES TO OFFICERS AND DIRECTORS
The President, Director, & Chairman of Earth Science Tech, Inc., as our independent auditor. ForNickolas S. Tabraue, received 200,000 shares of the yearsCompany’s common stock during the year ended March 31, 2014, and 2013, we incurred fees as discussed below:
| Fiscal Year Ended | ||
| March 31, 2014 | March 31, 2013 | |
| Audit fees | $_13,000_____ | $7,750 |
| Audit – related fees | Nil | Nil |
| Tax fees | 500 | 500 |
| All other fees | Nil | Nil |
The CEO & Chief Sales Officer, (CSO) of fees related to professional services rendered in connection withEarth Science Tech, Inc., Dr. Michel Aube, received 200,000 shares of the auditCompany’s common stock during the year ended March 31, 2019.
The Director & COO of our annual financial statements and reviewEarth Science Tech, Inc., Gagan Hunter, received 40,000 shares of our quarterly financial statements. Tax fees represent fees related to preparationthe Company’s common stock during the year ended March 31, 2019.
The CFO of our corporation income tax returns.
The former Chief Sales Officer, (CSO) of services, including planned services, project based services and routine consultations. In addition,Earth Science Tech, Inc., Jillian Buzan, received 10,400 shares of the audit committee may also pre-approve particular services on a case-by-case basis. Our audit committee approved all services that our independent accountants provided to us inCompany’s common stock during the past two fiscal years.
The Chief Sales Officer, (CSO) of Earth Science Tech, Inc., David Barbash, received 7,000 shares of the Company’s common stock during the year ended March 31, 2019.
During the fiscal year ended March 31, 2019 we incurred approximately $33,040.00 in audit fees to our principal independent accountants for professional services rendered in connection with the audit of financial statements for the fiscal year ended March 31, 2019. During the fiscal year ended March 31, 2019 we incurred approximately $38,427 in audit fees to our principal independent accountants for professional services rendered in connection with the audit of financial statements for the fiscal year ended March 31, 2019.
During the fiscal year ended March 31, 2019, we did not incur any other fees for professional services rendered by our principal independent accountants for all other non-audit services which may include, but not limited to, tax related services, actuarial services or valuation services. During the fiscal year ended March 31, 2019, we incurred professional services fees of $158.00 rendered by our principal independent account for tax services.
BF Borgers is furnished and not filed or a partthe Company’s principal auditing accountant firm. The Company’s Board of a registration statement or prospectus for purposesDirectors has considered whether the provisions of Sections 11 or 12audit services are compatible with maintaining BF Borgers’s independence. The engagement of our independent registered public accounting firm was approved by our Board of Directors prior to the start of the Securities Actaudit of 1933, as amended, is deemed not filedour consolidated financial statements for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
The following table represents aggregate fees billed to the requirements ofCompany for the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
The following exhibits are incorporated into this Form 10-K Annual Report:
None.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RECEIVER FOR EARTH SCIENCE TECH, INC. CASE NO. A-18-784952-C STRONGBOW ADVISORS, INC. | ||
| Dated: July 1, 2019 | By: | /s/ Robert Stevens |
| Robert Stevens | ||
| Its: | President | |
| EARTH SCIENCE TECH, INC. | ||
| Dated: July 1, 2019 | By: | /s/ Nickolas S. Tabraue |
| Nickolas S. Tabraue, under the supervision and direction of Robert Stevens and Strongbow Advisors, Inc., receiver for Earth Science Tech, Inc. Case No. A-18-784952-C | ||
| Its: | President, Director, & Chairman | |